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In autism, abnormalities in growth 
and development of brain structures 
have been detected as well as altera-
tions in the serotonergic system. This 
study investigated the relationships 
between growth factors, monoam-
inergic transporters and autism in 
children. The efficacy of fluoxetine, a 
selective serotonin reuptake inhibi-
tor, on these parameters was evalu-
ated. Positive effects on the clinical 
symptoms of autism were detected, 
indicating that fluoxetine might 
represent a useful adjunct to other 
therapies in children with autism.
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ABSTRACT 
Autism is a neuropsychiatric developmental disorder in which there is a dysfunction in 
social interaction and communication, and a combination of repetitive and stereotypic 
behavior. Disturbances in growth factors and monoaminergic neurotransmitter system 
have been postulated in autism. Selective serotonin reuptake inhibitors (SSRIs) have 
shown favorable effects in autism, and effects on growth factors elsewhere, but the 
relationships between these elements have not been investigated. 
Prior to treatment, head circumference (HC) was registered and insulin-like growth 
factor-1 (IGF-1) was measured in cerebrospinal fluid (CSF) in 25 children with autism, 
aged 2 to 16 years. Serum brain derived neurotrophic factor (BDNF) was analyzed and 
serotonin transporter (SERT) and dopamine transporter (DAT) binding were determined 
by single photon emission computed tomography (SPECT) in 15 autistic children, aged 5 
to 16 years. Control groups were composed of 16 and 10 age-matched children without 
autism, aged 1 to 15 years and 7 to 14 years, respectively. 
Six-months’ treatment with fluoxetine, an SSRI drug, was provided to 13 autistic 
children and symptoms were followed up using Autism Treatment Evaluation Checklist. 
The prior to treatment procedures were repeated 2 months after termination of treatment. 
Before treatment, CSF-IGF-1 concentration was lower in children with autism under 5 
years of age (p=0.014) than in controls. A positive correlation was detected between CSF-
IGF-1 and HC in autistic children (p=0.014). BDNF displayed a bimodal distribution in 
autistic individuals; concentrations were very low or high as compared with controls. 
At baseline, SERT binding capacity in SPECT was lower in autistic children in medial 
frontal cortex (p=0.002). Striatal DAT binding capacity was highest in the youngest autistic 
children, and then decreased with age, but in controls binding capacity increased with age. 
Fluoxetine elicited positive effects in communicative skills, sociability, and sensory 
awareness, particularly in six autistic children. These good responders exhibited a 
decrease in BDNF (p=0.03) as well as in striatal DAT binding (p=0.03). CSF-IGF-1 increased 
(p=0.003) but no correlation was detected with rates of clinical response. Fluoxetine was 
well tolerated.  
In conclusion, fluoxetine seems to modulate IGF-1, BDNF and the monoaminergic 
system, which are altered in autism. Fluoxetine could represent a useful adjunct therapy to 
conventional communication and behavioral therapies for children with autism. 
 
National Library of Medical Classification: WS 350.8.P4, QU 107, QU 55.2, QV 126 
Medical Subject Headings: Autistic Disorder; Brain-Derived Neurotrophic Factor; Child; Dopamine Plasma 
Membrane Transport Proteins; Fluoxetine; Insulin-Like Growth Factor I; Serotonin Plasma Membrane 
Transport Proteins 
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TIIVISTELMÄ 
Autismi on neuropsykiatrinen kehityksellinen häiriö, joka ilmenee sosiaalisen 
vuorovaikutuksen ja kommunikoinnin poikkeavuutena sekä toistavana ja kaavamaisena 
käyttäytymisenä. Autismiin on esitetty liittyvän kasvutekijöiden ja monoaminergisen 
välittäjäainejärjestelmän häiriöitä. Selektiivisten serotoniinin takaisinoton estäjien (SSRI-
lääkkeet) hyödystä autismissa on raportoitu ja havaittu niiden vaikuttavan 
kasvutekijöihin, mutta näiden seikkojen välisiä yhteyksiä ei ole tutkittu. 
Ennen hoitoa mitattiin päänympärysmitta (HC) sekä määritettiin insuliininkaltaisen 
kasvutekijä-1:n (IGF-1) pitoisuus selkäydinnesteessä (CSF) 25:ltä 2-16 vuotiaalta 
autistiselta lapselta. Seerumin aivoperäisen hermokasvutekijän (BDNF) pitoisuus 
määritettiin ja serotoniinin kuljettajaproteiinin (SERT) ja dopamiinin kuljettajaproteiinin 
(DAT) sitomiskapasitetti mitattiin yksifotoniemissiotomografiaa (SPECT) käyttäen 15 
autistiselta lapselta. Kontrolliryhmiin otettiin 16 ja 10 vastaavanikäistä ei-autistista lasta. 
Kuuden kuukauden fluoksetiinihoito (SSRI-lääke) toteutettiin 13 autistiselle lapselle 
joiden oireita seurattiin Autism Treatment Evaluation Checklist–menetelmällä. Ennen 
hoitoa tehdyt tutkimukset uusittiin kaksi kuukautta hoidon päättymisen jälkeen.  
Ennen hoitoa CSF-IGF-1 oli alhaisempi alle 5-vuotiailla autistisilla lapsilla (p=0.014) 
kontrolleihin verrattuna. Autistisilla lapsilla havaittiin CSF-IGF-1:n ja HC:n välillä 
riippuvuus (p=0.014). BDNF-pitoisuudet jakautuivat autisteilla kaksihuippuisesti; 
pitoisuudet olivat joko hyvin matalat tai korkeat verrattuina kontrolleihin. 
Ennen hoitoa SERT sitomiskapasiteetti oli autistisilla lapsilla matala otsalohkon 
sisemmällä kuorikerroksella (p=0.002). Striatumin alueella DAT sitomiskapasiteetti oli 
korkea nuorimmilla autistisilla lapsilla ja se väheni iän myötä. Kontrolleilla DAT 
sitomiskapasiteetti lisääntyi iän myötä.  
Fluoksetiinihoidon myötä todettiin suotuisia vaikutuksia kommunikaatiotaidoissa, 
sosiaalisuudessa sekä sensorisessa tietoisuudessa. Vaikutus oli erityisen selvä kuudella 
autistisella lapsella; heillä BDNF-pitoisuus aleni (p=0.03) ja striatumin DAT 
sitomiskapasiteetin väheni (p=0.03). Fluoksetiini lisäsi CSF-IGF-1-pitoisuuksia (p=0.003), 
mutta riippuvuutta kliiniseen vasteeseen ei havaittu. Fluoksetiinihoito oli hyvin siedetty. 
Fluoksetiini näyttää siis muokkaavan IGF-1:a, BDNF:a sekä monoaminergistä 
järjestelmää, joiden toiminta on muuttunut autismissa ja se saattaisi olla hyödyllinen lisä 
autististen lasten perinteisissä kommunikaatio- ja käyttäytymisterapioissa. 
 
Luokitus: WS 350.8.P4, QU 107, QU 55.2, QV 126 
Yleinen suomalainen asiasanasto: autismi; kasvutekijät; lapset  
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1 Introduction  
 
Autism is a neuropsychiatric developmental disorder characterized by a core impairment 
in social interaction, abnormalities in communication, and a markedly restricted, repetitive 
and stereotyped behavior and repertoire of interests (World Health Organization, 1993, 
American Psychiatric Association, 2000). According to the diagnostic criteria of childhood 
autism, the clinical symptoms should appear by the age of three years. The first clinical 
symptoms and signs include typically disturbance in eye contact and facial expressions, 
and a delay in vocalizing (babbling) and using communicative speech. The parents and 
other caregivers become usually aware of the aberrant development during the child´s 
second year, but abnormal signs can often be recalled from the first year of life. There is a 
subgroup of autistic infants who first develop social and communicative skills with 
normal milestones, but then go through an autistic regression and become withdrawn and 
do not progress as normal.  
Autism is currently considered as a continuum of pervasive developmental disorders, 
the autism spectrum disorder (ASD), rather than a constellation of separate entities. The 
etiology of autism is obscure but a heterogeneous concept with divergent backgrounds 
and relations, with alterations in genetic, neuropathological, neurophysiologic, 
immunologic and behavioral systems have been suggested (Muller, 2007). The impact of 
genetic factors is acknowledged based on family and twin studies (Folstein and Rutter, 
1977), and on an overexpression of autism in several genetic syndromes (Miles, 2011).  
Intrauterine and environmental conditions during pregnancy have been suspected since 
an increased risk for ASD has been detected in twins born with an affected co-twin, as 
compared with the risk for ASD in siblings born from separate pregnancies (Rosenberg et 
al., 2009). However, no evidence of any consistent perinatal or neonatal factor has been 
implicated with an elevated risk of autism (Gardener et al., 2011).  
Abnormalities in brain growth patterns and neuropathological structures of brain have 
been reported in autistic individuals (Courchesne et al., 2003 and 2011). A diminished 
number of the cerebellar Purkinje cells have been found in post-mortem studies in autism. 
This suggests that the perturbation in the coordinating and inhibiting role of cerebellum 
may have an important impact in the pathogenesis of autism (Bauman and Kemper, 2005).  
In autism, neurotransmitters, and especially the serotonin system have been an object of 
interest. Serotonin acts as a transmitter in the mature brain, but it is also a growth factor 
and a neuronal modulator in the prenatal and postnatal development of neuronal 
networks (Whitaker-Azmitia, 2001). The earliest observation in the 1960’s of a possible 
dysfunction concerning serotonin in autism was can be traced in the detection of 
hyperserotonemia in one third of autistic subjects (Schain and Freedman, 1961).  
Pharmacological agents with target on serotonin, including the selective serotonin 
reuptake inhibitors (SSRIs) have been used to relieve symptoms in several psychiatric and 
neuropsychiatric disorders, including autism (Kolevzon et al., 2006). The connections 
between the SSRIs and neurotrophins, the growth factors regulating the neuronal survival, 
differentiation and synapse formation, have been detected (Hodes et al., 2010, Aleman and 
Torres-Aleman, 2009). The effect of SSRIs in the behavioral features in autistic children has 
been studied (McDougle et al., 1996, DeLong et al., 2002, Hollander et al., 2005, King et al., 
2009) but the influence on the neurotrophins has not been elucidated in autism. 
The aims of the present study were to measure the neuronal growth factors (IGF-1, IGF-
2 
 
 
 
2 and BDNF) and the monoaminergic neurotransmission system, serotonin transporter 
(SERT) and dopamine transporter (DAT), and to evaluate the effects of fluoxetine, an SSRI 
drug, in the above-mentioned factors and the clinical picture of autistic symptoms and 
behavior in a group of autistic children aged between 2 and 16 years. 
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2 Review of the literature 
 
2.1 HISTORICAL ASPECTS AND DIAGNOSTIC CRITERIA OF AUTISM 
2.1.1 History 
The autistic disorder was first described by the Austrian born, American psychiatrist Leo 
Kanner (1943). In his visionary paper describing 11 pediatric patients with “autistic 
disturbances of affective contact”, Kanner depicted out a spectrum of behavioral 
manifestations and diverse presence of these children. Kanner adopted the term “early 
infantile autism” to underline the fact that the origins of this disorder develop early in the 
infancy. Kanner suspected that pathology in the personality of the parents – especially 
emotional coldness of the mothers – would be responsible for the child´s development to 
become autistic (Kanner, 1949) and this impression lived for decades on.  
In general, autism was considered as a part of a schizophrenic process in children 
(Cappon, 1953). In the diagnostic descriptions and classifications of diseases, autism was 
classified as a variation of childhood schizophrenia or atypical psychosis until for the first 
time it appeared as a distinct medical entity in the International Classification of Diseases 
(ICD) 9th revision published by the World Health Organization in 1979. ICD is a manual 
widely used in Europe, including Finland. The corresponding American manual, the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) published by the American 
Psychiatric Association introduced autism as a separate disease in its 3rd revised version 
(DSM-III) in 1980. 
In the most recent updates of these manuals, ICD-10 Classification of Mental and 
Behavioural Disorders: Diagnostic Criteria for Research in 1993 and DSM-IV Text Revision 
in 2000, the concept of autism was broadened to autism spectrum disorder (ASD), 
including childhood autism, Asperger syndrome, Rett syndrome, childhood disintegrative 
disorder, and pervasive developmental disorder not otherwise specified. 
 
2.1.2 Diagnostic criteria and diagnostic tools in autism 
There is no biochemical marker for autism or autism spectrum disorders. The diagnosis is 
entirely depending on the clinical symptoms and signs detected during the development 
of the child. The diagnostic criteria have three main domains; the functional impairments 
in social interaction, communication and behavior. The ICD-10 criteria for childhood 
autism are presented in Table 2.1. 
The diagnostic criteria provide a base for a broad spectrum of diverse phenotypes; the 
patients may differ widely in the degree of impairment in the core symptoms, and also in 
aspects of their intellectual capacity and adaptive abilities. Furthermore, the individual 
manifestation may vary during the development from infancy to adulthood. 
The diagnostic boundaries between the different autism spectrum disorders are defined 
by timing in the onset of symptoms, and the qualitative contents of the symptoms. The 
criterion separating most clearly childhood autism from Asperger syndrome is the 
development of language; in childhood autism there is a severe delay in the development 
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of spoken language before the age of 3 years, but in Asperger syndrome spoken or 
receptive language developes normally during the early years. Secondly, in childhood the 
cognitive development has a wide variation from severe mental retardation to high 
intelligence levels, but for criteria of Asperger syndrome, no general delay in cognition is 
allowed. There is a subgroup of ASD patients with regression in language and/or other 
communication skills after the age of 3 years or a repertoire of symptoms that do not 
completely fit the criteria of either autism or Asperger syndrome either, and this 
population is defined to present atypical autism or pervasive developmental delay not 
otherwise specified. 
The most commonly used tests in clinical evaluation of childhood autism include 
Childhood Autism Rating Scale (CARS) (Schopler et al., 1988), Autism Diagnostic 
Interview –Revised (Lord et al., 1994), and Autism Diagnostic Observation Schedule (Lord 
et al., 2000). These tests are used by professionals. 
In addition, there are tests, especially made for searching subjects with Asperger’s 
syndrome or individuals with autistic traits in the general population, including 
Childhood Autism Spectrum Test or Childhood Asperger Screening test as it was called 
formerly (Williams et al., 2006), Asperger Syndrome Screening Questionnaire (Ehlers et al., 
1999), and the Autism Spectrum Quotient (Baron-Cohen et al., 2001), typically used as 
screening tools, not as real diagnostic instruments. 
The separation of entities in ASD may be difficult to determine in clinical practice: the 
diagnostic category the individual best represents may change over time. There has been 
discussion in the literature that especially the line is imaginary between the autistic 
patients with no cognitive developmental delay (the high functioning autism), and those 
with Asperger syndrome, despite the differences in their early language skills 
(Noterdaeme et al., 2010). 
There has been proposal for the next revisions of DSM-5, scheduled in 2013, and ICD-
11, scheduled in 2015, to remove the definitions between the subgroups and diagnose ASD 
as only a single entity (www.dsm5.org). However, there is no consensus in this and there 
is an on-going discussion (Wing et al., 2011, Mattila et al., 2011). 
 
Table 2.1.International Classification of Diseases 10th revision (ICD-10) Criteria for Childhood 
Autism (F84.0). 
A. Abnormal or impaired development is evident before the age of 3 years in at least one of the 
following areas: 
 
1. receptive or expressive language as used in social communication;  
2. the development of selective social attachments or of reciprocal social interaction;  
3. functional or symbolic play.  
 
B. A total of at least six symptoms from (1), (2) and (3) must be present, with at least two from (1) 
and at least one from each of (2) and (3)  
 
1.  Qualitative impairment in social interaction are manifest in at least two of the following  
  areas:  
 a. failure adequately to use eye-to-eye gaze, facial expression, body postures, and gestures 
  to regulate social interaction;  
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 b. failure to develop (in a manner appropriate to mental age, and despite ample 
 opportunities) peer relationships that involve a mutual sharing of interests, activities and 
 emotions;  
 c. lack of socio-emotional reciprocity as shown by an impaired or deviant response to 
 other people’s emotions; or lack of modulation of behavior according to social context; or a 
 weak integration of social, emotional, and communicative behaviors;  
 d. lack of spontaneous seeking to share enjoyment, interests, or achievements with other 
 people (e.g. a lack of showing, bringing, or pointing out to other people objects of interest 
 to the individual).  
 
2.  Qualitative abnormalities in communication as manifest in at least one of the following  
  areas: 
 a. delay in or total lack of, development of spoken language that is not accompanied by an 
 attempt to compensate through the use of gestures or mime as an alternative mode of 
 communication (often preceded by a lack of communicative babbling); 
 b. relative failure to initiate or sustain conversational interchange (at whatever level of 
 language skill is present), in which there is reciprocal responsiveness to the 
 communications of the other person;  
 c. stereotyped and repetitive use of language or idiosyncratic use of words or phrases;  
 d. lack of varied spontaneous make-believe play or (when young) social imitative play  
 
3.  Restricted, repetitive, and stereotyped patterns of behavior, interests, and activities are 
 manifested in at least one of the following:  
 a. An encompassing preoccupation with one or more stereotyped and restricted patterns 
 of interest that are abnormal in content or focus; or one or more interests that are abnormal 
 in their intensity and circumscribed nature though not in their content or focus;  
 b. Apparently compulsive adherence to specific, nonfunctional routines or rituals;  
 c. Stereotyped and repetitive motor mannerisms that involve either hand or finger 
 flapping or twisting or complex whole body movements;  
 d. Preoccupations with part-objects of non-functional elements of play materials (such as 
 their odor, the feel of their surface, or the noise or vibration they generate).  
 
C. The clinical picture is not attributable to the other varieties of pervasive developmental 
disorders; specific development disorder of receptive language (F80.2) with secondary socio-
emotional problems, reactive attachment disorder (F94.1) or disinhibited attachment disorder 
(F94.2); mental retardation (F70-F72) with some associated emotional or behavioral disorders; 
schizophrenia (F20) of unusually early onset; and Rett Syndrome (F84.12).  
 
 
2.2 EPIDEMIOLOGY 
The prevalence of childhood autism or ASD has been inconsistent in reports from different 
populations and at different times. The changing diagnostic criteria (or differences in 
interpretation and impression of the criteria) in different time periods have made it 
difficult to compare the results across the studies.  
In early epidemiological studies up to 1990’s, a prevalence rate of childhood autism was 
concluded to be from 4 to 5 per 10,000 children in reviews by Fombonne (1996) and 
Gillberg and Wing (1999). In his review, Fombonne (1996) estimated the minimum 
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prevalence of ASD as 20 in 10,000 children. Since then, the prevalence has been elevated in 
most reports, and in a review only a few years later (Charman, 2002) the prevalence of 
autism was reported to rise up to 40 in 10,000, and prevalence of all ASDs up to 70 in 
10,000 children. The gender distribution was highly male-dominated; 73 to 88 percent of 
all ASD patients were males (Charman, 2002). In Sweden, in 1999 Kadesjö et al. reported a 
prevalence of ASD to be 1.2% in a cohort of 826 children born in 1985, at age of 7 years. All 
the 10 children with ASD (5 with autistic disorder, 4 with Asperger syndrome, and 1 with 
autistic like condition) were assessed as needing special education or personal assistants in 
normal class-rooms. 
In Finland, the prevalence of autism was first published by Kielinen et al. (2000) 
presenting the prevalence of autism in the population of the Northern Finland born from 
1979 to 1994. They reported the prevalence of “classic autism” 5.6 in 10,000 and that of 
“autism and autism-like syndromes” 14 in 10,000. The prevalence in boys was four times 
higher than that in the girls.  The degree of autism was assessed by CARS and notably 
high proportion of the subjects had moderate or severe autistic features, 59% and 33% 
respectively (Kielinen et al., 2000).  
In a preliminary report based on national hospital registers and concerning the 
complete Finnish population born between the years 1987 and 2005, a prevalence of 10 in 
10,000 for childhood autism and 46 in 10,000 with ASD was estimated (Lampi et al., 2011). 
A 4:1 male-female distribution for childhood autism and for total ASD was detected in 
that study. In patients with Asperger syndrome, the male-domination is even greater: 5 
males for 1 female (Lampi et al., 2011). 
In a recently published epidemiological study targeting all 8-year-old children (n = 
5,484) born in 1992 and living in a defined area of Northern Finland, reported the 
prevalence of ASD as 84 in 10,000 and that of autism 41 in 10,000 according to DSM-IV 
Text Revision criteria (Mattila et al., 2011). 
In another Nordic country, Denmark, the prevalence for childhood autism in children 
younger than 10 years has been reported to be 12 in 10,000, and the prevalence for ASD as 
35 in 10,000 (Lauritsen et al., 2004). In this report almost half of the ASD prevalence, 18 in 
10,000, comprised of individuals with atypical autism or pervasive developmental 
disorder –not otherwise specified. 
In the United States of America, a repetitive surveillance concerning children aged 8 
years has reported the  prevalence of ASD to have increased from 57 in 10,000 subjects in 
2000 up to 90 in 10,000 subjects in 2006 (Centers for Disease Control and Prevention , 2007 
and 2009). The Centers for Disease Control and Prevention reports did not separate the 
ASD cases more closely. Another recent report in the USA comparing the trends in 
developmental disorders in children aged 3-17 years elicited that prevalence in ASD had 
become more than threefold between the years 1997 to 2008, an increase from 19 to 74 per 
10,000 individuals (Boyle et al., 2011). In the last-mentioned report (Boyle et al., 2011), the 
male-dominance in ASD was 3 to 5 for 1 female, in different 3-year age cohorts. 
There are only a few epidemiological studies providing detailed information about the 
separate entities in ASD or comparing the epidemiology of autism with other psychiatric 
or neuropsychiatric disorders in children. A Danish cohort study published in 2007 
discovered an increase in the prevalence in ADHD, Tourette syndrome and obsessive-
compulsive disorder in childhood altogether, not simply increase in autism or ASD 
(Atladottir et al., 2007). In Massachusetts birth cohorts 2001-2005 the prevalence of the 
“classic” childhood autism remained the same (approx. 20 in 10,000) while the proportion 
of unspecified autism and PDD-NOS increased clearly (from 44 to 70 in 10,000) (Manning 
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et al., 2011), reaching a total ASD prevalence of 90 per 10,000 equal to the USA nationwide 
report in 2006 (Centers for Disease Control and Prevention, 2009).  
In a British survey of children aged 5-9 years, a total prevalence of ASD was 113 in 
10,000 children (Baron-Cohen et al., 2009). Interestingly, the researchers reported that 
during the study, they could detect 2 “new” cases meeting the ASD criteria for every 3 
earlier diagnosed subjects. Two-thirds of the “new” ASD cases were Asperger syndrome 
or high-functioning autism, the distribution of subgroups in the earlier diagnosed ASD 
cases were not reported.  
The increase in the number of reported diagnoses of autism, or ASD, has been under 
discussion during the past decades. Several factors are believed to be involved in this 
increase; improved awareness both in parents and in professionals in being able to 
recognize and detect autistic symptoms, as well as an increase in availability of diagnostic 
services might be responsible for part of the increase. In addition, since there are more 
broad diagnostic criteria in use, and accepting autism as a co-morbid condition with other 
medical conditions may explain the increasing and varying figures of prevalence in 
different studies (Baron-Cohen et al., 2009).  It has also been stated that the differential 
diagnosis between the presentations of autistic traits in the general population and the 
diagnostic criteria for ASD can be unclear. The definition of the severity of the symptoms 
or the behavior interfering the daily functioning are dependent on the environmental 
demands.  As the most recent studies from the United Kingdom and the USA indicate, the 
increase in ASD is mostly at the “milder” end of the spectrum, including Asperger 
syndrome, high-functioning autism, and pervasive developmental disorder not otherwise 
specified (Baron-Cohen et al., 2009, Manning et al., 2011). However, in spite of these 
explanations, some part of the increase in ASD prevalence remains unexplained and will 
require clarification. 
 
2.3 GENETIC FACTORS IN AUTISM 
The impact of genetics on autism has long been acknowledged based on several studies 
showing increased incidence of childhood autism and ASD in family members of the 
index person. According to a recent review, twin concordance in monozygotic twins has 
varied between 36 to 95%, and in dizygotic twins between 0 to 31% in different studies 
(Ronald and Hoekstra, 2011). The largest twin study so far published consisted of 67 
monozygotic and 120 dizygotic twin pairs, reported a pairwise autistic spectrum 
concordance of 88% for monozygotic twins and 31% for dizygotic twins (Rosenberg et al., 
2009). It was notable that the pairwise concordance was higher in male-male dizygotic 
twins than in female-female pairs. However, there was ASD concordance in all 9 female-
female monozygotic pairs in that study. 
The risk for ASD in siblings in a family with a child with autism or ASD has been 
reported between 3 to 10% (Chakrabarti and Fombonne, 2001, Lauritsen et al 2004). The 
stoppage effect, i.e. having no more children after ASD has been detected in one child may 
affect the overall risk in siblings. In a recent study, a higher risk of 19% of ASD recurrence 
in later-born siblings was detected, and the risk was higher in male (26%) than in female 
(9%) siblings (Ozonoff et al., 2011). 
The increased prevalence of autistic traits or the broader autistic phenotype without the 
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diagnostic criteria being fulfilled has been detected in siblings, parents or other relatives of 
ASD patients (Ruta et al., 2012). 
More than 100 disease genes and over 40 genomic loci have been linked with an 
increased risk of ASD (Betancur, 2011). The association between autism and fragile X 
syndrome was noticed already in the 1980´s (Brown et al., 1982). The genetic background 
for fragile X syndrome is a defect in fragile X mental retardation protein coding gene, the 
FMR1 gene (DeVries et al., 1998). Through FMR1 gene it has been possible to generate the 
first experimental animal model of autism, the FMR1 knockout mice (Dutch-Belgian Fragile 
X Consortium, 1994). 
In fragile X syndrome, up to 60% of patients have been reported to meet the ASD 
criteria. Although it is the leading known cause of autism, fragile X syndrome comprises a 
mere 2% of all ASD patients. In tuberous sclerosis complex, the prevalence of co-morbid 
ASD is up to 90% in mentally retarded patients but less than 20% in patients with normal 
intelligence. The reason behind this discrepancy remains unclear (Abrahams and 
Geschwind, 2008). 
Rett syndrome, a developmental disorder affecting almost exclusively females, is 
included in the autism spectrum in ICD-10 and DSM-IV. Rett syndrome was linked with 
mutations in the X-linked methyl CpG binding protein 2 (MeCP2) gene (Amir et al., 1999) 
In Prader-Willi and Angelman syndromes, which are both affected by disequilibrium of 
the genes in 15q11-13 locus, the prevalence of ASD has been reported to be increased 
(Veltman et al., 2005). The risk of ASD seems to be higher (25%) in individuals Prader-
Willi syndrome, and maternal uniparental disomy, or partial paternal deletion of the 
affected loci, than the risk of ASD (2%) in Angelman syndrome with paternal uniparental 
disomy or partial maternal deletion, respectively (Veltman et al., 20005). Interestingly, an 
overlap in the gene regulation pathways has been suggested in cases of Angelman 
syndrome, Rett syndrome, and (non-syndromic) autism (Jedele, 2007). 
It has been postulated that the neurobiological defect in autism could be considered as a 
synapsopathy as the deficient genes in fragile X syndrome, Rett syndrome, Angelman 
syndrome, and tuberous sclerosis have been associated with protein synthesis and 
neuronal plasticity in the synapse. Several single autistic candidate genes without 
syndromic endophenotypes have also proposed to influence synaptic function; with 
Neuroligins 1-4,  Neurexin 1, and SH3 and multiple ankyrin repeat domains 3 (SHANK3) 
being the most relevant (Ylisaukko-oja et al., 2005, Dolen and Bear, 2009). 
There are several metabolic conditions in which there are increased prevalences of ASD. 
Mitochondrial disorders have been identified in selected autistic subgroups with 
concomitant atypical features as failure to thrive, epilepsy or intermittent episodes of 
regression (Haas, 2010). Inborn errors in creatine metabolism have been linked with an 
increased incidence of autistic symptoms, although mental retardation and seizures 
usually dominate the clinical picture (Newmeyer et al., 2007). Smith-Lemli-Opitz 
syndrome, a disorder in cholesterol metabolism, has a reported rate of ASD of up to 75%, 
but no correlation between the abnormal metabolite concentrations and autism severity 
has been detected (Sikora et al., 2006). 
ASD patients with a “complex” phenotype, including dysmorphic features, 
microcephaly or alteration of early morphogenesis, are believed to be more likely, in 
approximately 25% of those individuals one finds, an autism associated syndrome or 
chromosome disorder in comparison with individuals with “essential” autism without the 
abovementioned features (Miles, 2011). It has also been stated that there are differences in 
the sex ratio, recurrence risk and family history between the complex (or “syndromic”) 
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autism and the essential autism, the latter having a higher male predominance, higher 
occurrence risk in siblings, and a greater likelihood of a family history of ASD (Miles, 
2011). 
Furthermore there are numerous gene loci variations listed as displaying an elevated 
frequency in autistic subjects, without any common syndrome features. These include 
variants in serotonin transporter gene alleles (Prasad et al., 2009) and BDNF gene 
polymorphism (Cheng et al., 2009). 
 
2.4 ABNORMALITIES IN BRAIN GROWTH AND STRUCTURE  
 
Already in his initial article Kanner (1943) mentioned that five of the examined 11 children 
had relatively large heads. Thereafter between 10 to 20% of autistic individuals have been 
reported to have macrocephalia, i.e. HC more than 2 standard deviations (SD) above 
average, and the macrocephaly trait has been observed also in the non-autistic family 
members (Miles et al., 2000). 
However, in the neonates with later ASD, HC at birth has been normal or slightly below 
the average, and then followed by an early overgrowth during the first 1 or 2 years. 
However, growth is slowed down thereafter and the brain volumes have been reported to 
be smaller than those of normal controls in their adulthood (Courchesne et al., 2007). The 
evolution of neuroimaging has provided opportunities to accurately measure structure 
and volumes of different regions of the brain. In magnetic resonance imaging (MRI) 
studies, the brain overgrowth in autism appears to be most prominent in the frontal and 
temporal lobes and in amygdala, and more apparent in gray matter than white matter 
(Carper and Courchesne, 2005). The regional overgrowth in early infancy seems to be most 
remarkable in those brain regions whose cognitive function is most severely impaired in 
later life (Courchesne et al., 2007). 
Akshoomoff et al. (2004) measured brain volumes of 52 autistic children aged 2 to 5 
years, and 15 typically developing age-matched children. The autistic children were 
divided into subgroups of high functioning autism, low functioning autism and pervasive 
developmental disorder not otherwise specified. The whole brain volume, overall cerebral 
volume and cerebral gray matter volume were discovered significantly larger in children 
with low functioning autism than in controls. The overall cerebellar volume did not reach 
significance but cerebellar white matter volume and cerebellar vermis lobules I-V areas 
were larger in all autistic subgroups than in typically developing children (Akshoomof et 
al., 2004). 
A recent longitudinal MRI study with multiple scans from 1.5 years up to 5 years of age 
on 41 children with low functioning autism confirmed that both gray matter and white 
matter volumes were enlarged by 2.5 years of age as compared with 44 typically 
developing controls (Schumann et al., 2010). The enlargement was most apparent in 
frontal, cingulate and temporal cortices with the percentage difference of 6%, 8%, and 9%, 
respectively. Total cerebral white matter volume was 10% larger and total cerebral gray 
matter volume 5% larger in autistic individuals than in controls. In that study, the growth 
pattern was more widespread and more severe in the 9 female autistic patients than in the 
32 autistic males (Schumann et al., 2010). 
A comparison between the HC and MRI studies has indicated that HC is an accurate 
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index of brain volume (and weight) in children less than 7 years of age (Bartholomeusz et 
al., 2002). In older children, the wide range of ventricular volume makes HC less precise. 
Diffusion tensor imaging studies in autistic patients have been published since 2004. 
The very first paper examined 7 children and adolescents with high functioning autism 
revealing abnormalities in white matter tracts as compared with those of 9 typically 
developing control subjects (Barnea-Goraly et al., 2004). Reduced fractional anisotrophy, a 
measure reflecting how diffusion varies along different directions, was observed in brain 
regions implicated in face and gaze prosessing, emotional prosessing, and those activated 
in theory of mind tasks, i.e fusiform gyrus, anterior cingulate, amygdala, ventromedial 
prefrontal cortex, temporoparietal junction, and superior temporal sulcus (Barnea-Goraly 
et al., 2004). Recently, the same research group reported likewise abnormalities in the 
frontal, parietal and temporal lobes of 13 autistic children as well as in their 13 unaffected 
siblings as compared with 11 controls (Barnea-Goraly et al., 2010). In the last-mentioned 
study, the abnormalities were not restricted to regions with importance for social 
cognition (Barnea-Goraly et al., 2010). Consistent with the findings of Barnea-Goraly et al., 
Jou et al. (2011) reported abnormalities in long-range cortico-cortical connectivity 
involving several association, commissural and projection tracts important for social 
cognition in 15 autistic boys, aged 5-17 years, as compared with 8 typically developed 
controls with the same age distribution. 
Macrocephaly persisting beyond the early childhood may present a familial genetic 
predisposition since the non-autistic family members of autistic children with 
macrocephaly have been reported to have even higher rates of macrocephaly (Fidler et al., 
2000). In the cases where there is very noticeable macrocephaly, a genetic background with 
mutations in phosphatase and tensin homolog (PTEN) gene has been reported in 24 
patients with autism (Conti et al., 2011). 
Considering the neuronal structure of brain in autism, the most consistent and repeated 
finding has been the decreased number of Purkinje cells in cerebellum, the structure with 
an important role in modulating cognitive and motor functions (Bauman and Kemper, 
1985 and 2005, Ritvo et al., 1986, Bailey et al., 1998,). The timing of the loss of the Purkinje 
cells has been estimated to occur before 28-30 weeks of gestation, according to earlier 
reported findings examining Purkinje cells´ connections to other brain structures (Rakic 
and Sidman, 1970).  
Maternal use of valproic acid, an antiepileptic and mood-stabilizer, during pregnancy 
has been shown to increase the risk of autism in children (Rasalam et al., 2005). In an 
experimental model of autism, mice exposed prenatally to valproic acid have been found 
to display significant reductions in Purkinje cell number and aberrations in dimensions of 
cerebellar structures similar to those encountered in autistic human patients (Ingram et al., 
2000). 
A decrease in the number of neurons in the amygdala, a part of limbic system known to 
be important in processing emotions, learning ,and memory, has been reported in autism 
(Schuman and Amaral, 2006). 
A disruption in the architecture of the neocortical minicolumns has been reported 
(Casanova et al., 2003). A theory proposing hyper-functioning neuropathology in the 
microcircuits has been presented, especially in the minicolumns but also in other brain 
structures (Markram and Markram, 2010). Experimental studies have suggested that there 
is a link between the prenatal effects of valproic acid and the neuropathology in the 
microcircuits, including the decreased number of inhibitory Purkinje cells (Ingram et al., 
2000). 
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2.5 GROWTH FACTORS IN AUTISM 
2.5.1 Insulin-like growth factors 
The amino acid sequences of human insulin-like growth factors IGF-1 and IGF-2 were 
subsequently determined and reported in 1978 (Rinderknecht and Humbel, 1978a and 
1978b). The broad spectrum of their stimulating effects on cellular proliferation and 
differentiation during fetal and postnatal development has been appreciated (Werther et 
al., 1998). 
In the brain, IGF-1 was initially considered as a neurotrophic factor involved in brain 
growth. Later, the IGF-1´s role in regulating brain function as a whole has become more 
evident. At present it is acknowledged that IGF-1 has many effects on the modulation and 
plasticity of neuronal circuits and connectivity (Torres-Aleman, 2010). Associations 
between cognitive function, intelligence, and IGF-1 have also been presented (Creyghton 
et al., 2004, Aleman and Torres-Aleman, 2009). There is evidence that IGF-1 is important in 
cerebellar development (Torres-Aleman et al., 1998, Werther et al., 1998), and the most 
consistent neuropathological findings in autism have been detected in cerebellum 
(Bauman and Kemper, 2005). Low IGF-1 concentrations have been reported in CSF of 
children with autism (Vanhala et al., 2001). On the other hand, Mills et al. (2007) detected 
elevated serum concentrations of IGF-1 and IGF-2 in autistic children between ages of 4 
and 8 years as compared with age-matched controls. They reported finding a positive 
correlation between IGF-1 and HC, but no correlation between IGF-2 and HC. 
Patients with symptomatic infantile spasms have been reported to exhibit markedly low 
CSF-IGF-1 concentrations as compared with those of children with idiopathic infantile 
spasms or control children (Riikonen et al., 2010). Low CSF IGF-1 concentrations were 
associated with a history of early insults or stress, and a poor response to treatment and a 
poor cognitive outcome (Riikonen et al., 2010). An increased future risk for ASD has been 
reported in children who have suffered infantile spasms, and recently this risk has been 
especially connected with the symptomatic origin of the seizures (Saemundsen et al., 
2008). In a rare Finnish genetic disorder, children with progressive encephalopathy, 
hypsarrhythmia (and infantile spasms), and optic nerve atrophy – the PEHO syndrome – 
have been reported to have low CSF-IGF-1 concentrations as compared with controls and 
“PEHO-like” patients without the typical neuroophtalmologic or neuroradiologic findings 
(Riikonen et al., 1999). 
A reduced concentration of CSF-IGF-1 than in controls has also been reported in 
infantile neuronal ceroid lipofuscinosis, a progressive encephalopathy with severe 
developmental delay emerging by the age of 3 years (Riikonen et al., 2000). 
No significant differences in serum IGF-1 concentrations were detected between 
children and adolescents with idiopathic epilepsy and controls (El-Khayat et al., 2010). 
Two antidepressants, fluoxetine and venlafaxine, have been shown to increase the 
concentration of IGF-1 and several other proteins associated with neurogenesis in the 
hippocampus in experimental studies (Khawaja et al., 2004). In a recently published paper 
in adult depressed patients treated with antidepressants, including fluoxetine, increases in 
CSF-IGF-1 were detected (Schilling et al., 2011). 
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2.5.2 Brain derived neurotrophic factor 
Brain derived neurotrophic factor (BDNF) was discovered in 1982 by Barde et al. who 
described it as a promoter of survival of neurons (Barde et al., 1982). BDNF belongs to the 
same family of neurotrophins as nerve growth factor and neurotrophin-3 and 
neurotrophin-4/5. BDNF and other neurotrophins bind to one or more of the tropomyosin-
related kinase receptors, which are members of the receptor tyrosine kinase family 
(Patapoutian and Reichardt, 2001). BDNF has survival and growth promoting actions on 
many different types of neurons, including hippocampal and cortical neurons (Huang and 
Reichardt, 2001). Physiologic regulation of BDNF gene is important in the development of 
brain; both excess BDNF and blockade of BDNF signaling during a critical period of 
development of visual cortex can lead to abnormal functionality (Cabelli et al., 1997). 
BDNF appears to have more multifaceted properties. In addition to its contribution to 
survival and development of neurons; it has a major influence on molecular mechanisms 
in synaptic plasticity and neurogenesis. This makes its role most interesting in 
neurobiological processes concerning learning and memory. The hippocampus has a 
crucial role in long-term memory, and this is an important site of BDNF action (Yamada 
and Nabeshima, 2003). BDNF and its receptor tyrosine kinase B (TrkB) play a major role in 
the action of antidepressant medication; experimental studies indicate that there are no 
behavioral effects of antidepressants in mice lacking the BDNF gene (Saarelainen et al., 
2003). BDNF infusion in hippocampus (Sirianni et al., 2010) and in raphe nucleus region 
(Siuciak et al., 1997) in rats has been able to mimick the effects of antidepressants. In 
contrast, rats receiving BDNF infusion in ventral tegmental area promoted a depression-
like effect as compared with control animals (Eisch et al., 2003). 
Nelson et al. studied (2001) BDNF in archived neonatal blood specimens from 
mandatory newborn screening, and detected increased concentrations of BDNF in those 
neonates who later were diagnosed with autism (n= 69) as well as  in those with non-
autistic mental retardation (n= 60), as compared with children with cerebral palsy (n=63) 
or controls with normal development (n=54). However, the recycled immunoaffinity 
chromatography method used in 2001 was later replaced with enzyme linked immune-
sorbent assay technology and when the same samples were re-evaluated with the new 
method, BDNF concentrations did not distinguish any longer the children with autism 
from the controls (Nelson et al., 2006). The neonatal blood sample study has later been 
repeated by Croen at al. (2008) and no differences were detected in BDNF concentrations 
between children with autism, intellectual disability or those enjoying normal 
development. Elevated concentrations of serum BDNF have been reported in pre-school-
aged children with autism and in childhood disintegrative disorder, a subgroup of ASD 
(Connolly et al. 2006). In another study, serum BDNF concentrations in school-aged 
children with autism and non-autistic mental retardation were significantly higher than 
those of adult controls (Miyazaki et al., 2004). There do appear to be differences between 
the serum concentrations of BDNF in autistic children and autistic adults. Hashimoto et al. 
(2006) have reported decreased BDNF in adult men with high functioning autism but no 
correlations were detected between clinical variables such as severity of autistic symptoms 
and BDNF concentrations.  
At time when the present study was conducted, there were no reports on the possible 
differences in BDNF concentrations of pre-pubertal children and pubertal adolescents. In 
the recent report of Iughetti et al. (2011), plasma BDNF concentrations were reported to be 
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lower in pubertal boys than in pre-pubertal boys, and both in pre-pubertal and pubertal 
girls.  
Additional support for the link between BDNF and autism has been provided by 
studies into those specific genetic disorders associated with autism. In Rett syndrome, the 
mutated protein MeCP2 regulates BDNF expression in complex manner. Cortical BDNF 
concentrations were reported to be reduced in a mouse model of Rett syndrome 
(Kaufmann et al., 2005). However, serum BDNF concentrations of Rett patients have not 
been shown to differ from those of healthy controls (Vanhala et al., 1998). In addition, 
BDNF polymorphism has been connected to modify disease severity in Rett syndrome 
(Zeev et al., 2009).  
In the fragile X syndrome, BDNF has been reported to regulate the expression of the 
fragile X mental retardation protein (Castren et al., 2002), and furthermore, BDNF 
polymorphism has been reported to influence the severity of seizures in fragile X patients 
with epilepsy (Louhivuori et al., 2009).  
 
2.5.3 Other growth factors 
Abnormalities in other neurotrophic factors have also been reported in autism. In a study 
investigating postmortem cerebellar tissue samples of 8 autistic patients, the concentration 
of neurotrophin-3 was found to be elevated as compared with equivalent samples of 7 
non-autistic control subjects (Sajdel-Sulkowska et al., 2009). The possible connection of 
neurotrophin-3 disequilibrium with the initial cerebellar overgrowth and a subsequent 
reduction of cerebellar Purkinje cells were also discussed in that report (Sajdel-Sulkowska 
et al., 2009). In the neonates who later had autistic development, serum neurotrophin was 
lower than control (Nelson et al., 2006). Serum neurotrophin-4 concentration was detected 
as being higher both in children with autism and children with non-autistic mental 
retardation than in adult controls (Miyazaki et al., 2004). 
 
2.6 NEUROTRANSMITTERS IN AUTISM 
The classical neurotransmitters are the small molecular weight compounds that transmit 
signals from one neuron to another on the other side of the synapse. Six of the major 
neurotransmitter systems are serotonergic, dopaminergic, noradrenergic, cholinergic, 
glutamatergic, and GABAergic systems, in view of the fact that the natural activating 
transmitters are serotonin, dopamine, norepinephrine, acetylcholine, glutamate and 
gamma-aminobutyric acid, respectively. 
In the synaptic regulation mechanism of nervous transmission, two different types of 
proteins, receptors and reuptake transporters, are the essential structures. The receptors 
act as targets for the transmitters on the post- and presynaptic structures, although 
receptors have also been detected on the soma and dendrites of the neurons, as well as on 
non-neuronal glial cells in the central nervous system (Barnes and Sharp, 1999). The 
reuptake transporters take up the transmitter molecules back after they have been secreted 
from the axonal terminal into the synaptic cleft. In that way the transporters can modify 
the intensity and duration of the signal. 
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2.6.1 Serotonin 
The serotonergic system has been the most intensively evaluated neurotransmitter system 
in autism. The serotonergic system seems to be involved in, or even to be responsible for 
many of the neuronal or behavioral perturbations observed in autistic individuals.  
Serotonin has been shown to act as an early regulator of brain development in 
experimental animals, and in humans (Whitaker-Azmitia, 2005). Schain and Freedman 
(1961) reported elevated blood serotonin concentrations in 6 out of 23 autistic patients. 
This has led to suggestions that high levels of serotonin may cause aberrations during the 
development of the neural circuits and connections and contribute to the emergence of 
autism. However, no consistent connection has been found between the blood serotonin 
concentration and autistic symptoms and behavior. However, there is some information 
about putative correlation between whole-blood serotonin concentration and cognitive 
functioning in autistic children and their close relatives (Cuccaro et al., 1993). Therapeutic 
methods aimed at reducing blood serotonin have not changed the clinical course in 
autistic children (Ritvo et al., 1971, Aman and Kern, 1989).  As a matter of fact, serotonin 
does not cross the blood-brain-barrier in adulthood although it is suspected that this may 
occur during early embryologic and fetal development (Whitaker-Azmitia, 2005). 
Medications affecting the serotonergic system during pregnancy have been investigated, 
and recently an increased risk of ASD was detected in mothers who had been prescribed 
SSRI medication. Croen et al. (2011) investigated 298 children with ASD and discovered 
that if an SSRI had been used during the year before delivery (including the pregnancy), 
this doubled the risk for ASD. The use of SSRIs during the first trimester of pregnancy 
increased the risk more than threefold. Prenatal exposure to SSRI was reported in 20 ASD 
cases (6.7%) compared with 50 of the 1507 (3.3%) randomly selected controls. The 
statistically calculated increase in ASD incidence owing to prenatal use of SSRIs was about 
2% in the Croen et al. study (2011).  
Serotonin transporter (SERT) is a protein located mainly on the presynaptic terminal of 
serotonergic neurons, but it has been detected also along axons, soma and dendrites of 
them, and it is believed to be the most important determinant of the extracellular level of 
serotonin in the central nervous system (Hoffman et al., 1998). SERT is also present in 
peripheral cells which are specialized in serotonin storage or inactivation, for example the 
platelets present in the peripheral blood (Carneiro and Blakely, 2006). Serotonin does not 
cross the blood-brain-barrier but the same gene produces SERT molecules in brain and in 
periphery (Lesch et al., 1993). 
The human SERT gene, SLC6A4 has been studied intensively in autism but it has not 
been possible to link common polymorphisms with the disease in families with autistic 
probands (Sutcliffe et al., 2005). Prasad et al. (2009) reported that rare functional variants 
in SERT gene may contribute to autism in some pedigrees, and there may be also an 
overlap with the obsessive compulsive disorder. One interesting finding was that the 
Gly56Ala variant of SERT gene evoked a selective effect on transmission only in males and 
the lack of transmission in unaffected females. Enhanced SERT activity was seen in several 
rare variants (Prasad et al., 2009). These observations are in concordance with the male 
predominance in autistic patients and the hyperserotonemia in blood and platelets in a 
minority of autistic individuals.  
In a functional imaging study of serotonin metabolism by positron emission 
tomography (PET), Chugani et al. (1997) detected asymmetric alterations in serotonin 
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synthesis in frontal cortex, thalamus and dentate nucleus of cerebellum in 7 autistic boys 
but not in an autistic girl as compared with their 5 healthy siblings. These findings were 
believed to correlate with abnormalities in language production and sensory integration 
both of which are affected in autism. In another study, Chugani et al. (1999) evaluated the 
serotonin synthesis capacity in the brains of 30 autistic children as compared with their 
healthy siblings and epileptic children without autism. In non-autistic children, serotonin 
synthesis capacity reached its maximum at age of 5 years, being then about 2-fold 
compared to that of adults, and then slowly declined towards adult values. In autistic 
children, the early peak in serotonin synthesis capacity was missing.  The serotonin 
synthesis capacity increased slowly until the age of 15 years, reaching then approximately 
values 1.5-fold of the adult values, thereafter slowly descending towards adult values. No 
gender dependence was detected, though the number of female autistic patients in the 
study was small – 6 out of 30. Furthermore, a linkage has been detected between the 
clinical developmental phenotype and the asymmetrical distribution of the aberrations in 
serotonin synthesis (Chandana et al., 2005); left sided cortical decrease in serotonin 
synthesis was associated with more severe language impairment. This may point to a link, 
and a disruption, in the development of the serotonergic system and the hemispheric 
specialization in autism.  
Abnormalities in serotonin receptor 2A binding in the cerebral cortex have been 
detected by SPECT in Asperger syndrome patients (Murphy et al., 2006) and altered SERT 
and/or serotonin receptor 1A functionality in hippocampus in a mice model of autism 
(Gould et al., 2011). 
In another experimental study, Boylan et al. (2007) induced a selective neonatal cortical 
serotonergic perturbation via injection of a neurotoxin into the medial forebrain bundle of 
the newborn mice.  Neuroanatomic and behavioral changes resembling those observed in 
human autistic subjects were observed in the affected mice (Boylan et al., 2007). An early 
postnatal depletion of cortical and hippocampal serotonin concentrations was followed by 
recovery towards adulthood in the mice in the Boylan et al. study (2007), these findings 
resembling those detected in the abovementioned studies by Chugani et al. (1999). Several 
behavioral changes were detected in the serotonin depleted mice i.e. impaired impulse 
inhibition, impaired exploratory activity and spatial memory, and alterations in social 
interaction and fine motor performance. Perhaps even more interesting, the behavioral 
aberrations were expressed much more clearly in male mice than in females, mimicking 
the gender distribution in autistic human population. 
Imaging SERT (and also dopamine transporter, DAT) by SPECT became possible in the 
early 1990’s when a radioligand, 123I-beta-CIT, became available (Brücke, 1993), and the 
method was rapidly adapted to use also in Finland (Kuikka et al., 1993). SPECT studies of 
SERT and DAT have been performed in several fields of adult neurology, including 
depression, panic disorder, anxiety disorder and eating disorders (Kuikka et al., 2001, 
Maron et al., 2004). The technique has also been introduced in pediatric neurology, 
including a study in fetal alcohol syndrome (Riikonen et al., 2005). However, no SPECT 
imaging of SERT in autistic patients had been performed until the present study. 
 
2.6.2 Dopamine 
Dopamine acts as a key neurotransmitter in several brain functions. Dopamine is involved 
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in the regulation of movement, reward and addiction, attentional mechanisms, cognitive 
functions, working memory processes, and in regulating and modulating emotional 
responses and social behavior (Nieoullon, 2002). Dopamine dysfunction has been reported 
to be related in several neuropsychiatric disorders, including  Tourette syndrome, 
attention deficit hyperactivity disorder (ADHD), bipolar disorder, schizophrenia, mania, 
obsessive-compulsive disorder, substance abuse, and autism (Gillberg and Billstedt, 2000). 
Several important dopaminergic tracts innervate amygdala and cingulate and prefrontal 
cortex which are core locations of neuroanatomic aberrations detected in autistic patients 
as well as in experimental models for autism (see Chapters 2.4 and 2.5). 
The characteristics of the motor disturbances in autism and their similarities with those in 
Parkinson’s disease have been noted. Since a good response of L-dopa to motor 
components in Parkinson’s disease had been detected, L-dopa treatment was also 
investigated in autistic patients (Ritvo et al., 1971). The decision to use L-dopa for 
treatment in autism was also linked to L-dopa’s ability to decrease blood serotonin 
concentrations in experimental studies. Indeed, Ritvo et al. (1971) found blood serotonin 
concentrations decreased in 3 out of 4 children after 6 months of L-dopa treatment, but no 
change was detected in the motor function or in the autistic behavior. 
The dopaminergic systems are considered to have major importance in the 
identification and modulating emotional stimuli, production and regulation of affective 
states and in the control of the flow of information from other areas of brain (Salgado-
Pineda et al., 2005), and all  those functions are suggested to be affected in autism.  
Prenatal genetically predisposed alterations in dopamine metabolism have been related 
with an increased risk of autistic development (Robinson et al., 2001). Furthermore, other 
environmental factors generating a hyperdopaminergic state have been postulated to act 
as an epigenetic factor to promote autistic expression (Previc, 2007). 
Reduced pre-frontal dopaminergic activity has been detected in 14 autistic children in a 
PET study by Ernst et al (1997). They reported that the difference was especially 
prominent in the autistic children with IQ higher than 80. Nieminen-von Wendt et al. 
(2003) published a PET study of 8 adult male patients with Asperger syndrome using the 
same tracer as Ernst et al in 1997, and reported increased blood flow in the striatum and 
the frontal cortex.  
Prior to the present study, there was only one SPECT study of imaging of DAT in 
autistic patients: Xiao-Mian et al. (2005) reported increased DAT binding in striatum in 10 
autistic children aged 3-10 years, as compared to their age-matched controls.  
However, several studies in other neuropsychiatric disorders with a high co-morbidity 
with autism have reported abnormalities in the dopaminergic system: in patients with 
obsessive-compulsive disorder, increased DAT binding in the basal ganglia was detected 
by Kim et al.  (2003) and in a further study (2007) a decrease in DAT density was detected 
in all 10 patients with obsessive compulsive disorder who had been treated with SSRIs 
during the previous 16 weeks, achieving also a decrease in symptoms. 
 Increased DAT binding in basal ganglia has also been reported in children with ADHD 
(n=9), and in children with Tourette’s disorder (n=9), as compared with healthy controls in 
studies published by Cheon et al. in 2003 and 2004, respectively.  
PET studies suggest abnormalities in both serotonergic and dopaminergic functions 
(Rumsey and Ernst, 2000). Dopaminergic and serotoninergic pathways originate in 
brainstem but project their axons to the forebrain. Serotonin is believed to play a critical 
interactive and modulating role with both of these systems in autism. DAT is an essential 
element in the function of the dopaminergic system (Gadow et al., 2008, Hettinger et al., 
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2008). 
Significant clinical benefits have been achieved with treatment with dopamine-2 
receptor antagonists, especially risperidone, emphasizing the importance of dopamine 
dysfunction being behind the autistic symptoms and behavior. Small doses of L-dopa have 
improved the sleep-wake cycle, aggressiveness and hyperkinesias in autistic individuals 
(Segawa, 2006), and this probably takes place through desensitization of the dopamine 
receptors. 
 
2.6.3 Other neurotransmitters 
Norepinephrine is a neurotransmitter synthesized from dopamine. Elevated plasma 
concentrations of norepinephrine have been reported in autistic children, especially in 
those with coexistent hyperserotonemia (Cook et al., 1990). However, most of the studies 
examining the norepinephrine system in autism have resulted in inconsistent findings and 
therefore it has been proposed that norepinephrine may have only a minor role in the 
expression and etiology of autism (Lam et al., 2006). 
Acetylcholine is the neurotransmitter released in the cholinergic system, and it is found 
in several sites in the central nervous system. The cholinergic system has been considered 
to act in developing the ability to focus on the environment and helping the individual to 
achieve a coherent behavioral response (Janowsky et al., 1994). It has been hypothesized 
that alterations in this system could be linked with problems with attention or learning in 
autism. In post-mortem studies of autistic brains a significant reduction was detected in 
acetylcholine binding to nicotinic receptors in the parietal and frontal cortexes as well as to 
muscarinic receptors in the parietal cortex. The relation of these findings to clinical 
symptoms or the etiology of autism remains obscure (Martin-Ruiz et al., 2004). 
 
2.7 OTHER FIELDS OF ETIOPATHOGENETIC RESEARCH 
2.7.1 Immunologic aberrations in autism  
The role of the immune system has been widely discussed considering the elevated risk of 
autism. Abnormalities in both innate and adaptive immune responses have been reported 
(Gupta et al., 2010) and the presence of various types of autoantibodies attacking nervous 
system components has been detected (Connolly et al., 2006, Singer et al., 2006). Damage 
to the blood-brain barrier and/or pathological activation of the brain immune response 
system due to unknown pathogenic factors has been proposed to be behind these 
aberrations (Meyer et al., 2006). Connolly et al. (2006) detected elevated levels of 
autoantibodies to brain endothelial cells, myelin basic protein, and BDNF in autistic pre-
school aged children, but the findings were not specific to autism and occurred also in 
children with epilepsy or non-neurological illnesses. Autoantibodies to cerebellar neural 
cells have been detected in other studies (Wills et al., 2009, Goines et al., 2011). 
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2.7.2 Infections and vaccinations 
Rubella and cytomegalovirus infections during pregnancy have been implicated as risk 
factors for autism in the developing child (Chess, 1971, Stubbs et al., 1984). Childhood 
immunizations given for the protection against several infectious diseases especially 
during the first and second year of life have been a cause of concern, due to beliefs that 
they may increase the risk of autism. The study of Wakefield et al., published in 1998, 
claimed that there was a link between measles, mumps, and rubella vaccination and 
autism. This attracted much media attention and caused considerable worry in parents 
and even mistrust of the public health services. Several epidemiological studies during the 
following years in different countries found no link between the measles, mumps and 
rubella vaccination and autism, and finally 12 years after its publication, the Wakefield 
study was found to have been fraudulent and it was retracted by the journal (Editors of 
the Lancet, 2010). 
 
2.7.3 Prenatal and environmental risk factors  
The incomplete concordance for autism in monozygotic twins and the increased risk in 
dizygotic twins compared with singleton-born siblings of an individual with ASD 
(Rosenberg et al., 2009) has raised interest in the environmental risk factors during the 
prenatal development.  
There are several chemicals known to be toxic during human neurodevelopment, 
including valproic acid, thalidomide, misoprostol and ethanol (Dufour-Rainfray et al., 
2011). The tragedy of thalidomide embryopathy although typically associated with severe 
limb anomalies has also been reported to be linked with an increased incidence of autism 
(Stromland et al., 1994). Misoprostol, used as an abortifacient agent, has led to a high 
proportion of autism in the children born following unsuccessful abortion attempts 
(Bandim et al., 2003).  
Children exposed to valproic acid have exhibited a variation of somatic malformation 
referred as the fetal anticonvulsant syndrome which carries also an increased risk of 
autism (Moore et al., 2000). In a recent study with 260 children with prenatal exposure to 
antiepileptic drugs,  the risk for autism spectrum disorder with any of them was 1.9-4.6%, 
but the risk associated with valproic acid (alone or in combination with other antiepileptic 
drugs) was 11.7% (Rasalam et al., 2005). The possible mechanism of valproic acid in the 
pathogenesis of autism has been presented in chapter 2.4. 
The connection between prenatal ethanol exposure and autism has been investigated in 
a recent study describing a 10% prevalence of autism among 21 children with fetal alcohol 
syndrome adopted from Eastern Europe (Landgren et al., 2010). However, no correlation 
between prenatal alcohol exposure and ASD was detected in a large populationbased 
study of more than 80 000 children and their mothers (Eliasen et al., 2010). The average 
alcohol consumption and episodes of binge drinking were very low in the latter study and 
the incidence of fetal alcohol syndrome was not investigated.  
In the USA in 2003, a large study was started called the Childhood Autism Risks from 
Genetics and Environment (The CHARGE Study) which recruits children born in 
California, and living there at age of 2 to 5 years, to collect and evaluate information about 
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chemical and biological exposures, susceptibility factors and their interactions (Herz-
Picciotto et al., 2006). The study population has been composed of children with a defined 
diagnosis of autism, other types of developmental delay, or typical development, and a 
total number of 2000 participants have so far been  collected (Herz-Picciotto et al., 2006).  
Until September 2011, a total of 12 papers from the CHARGE study have been published 
including reports on some immunologic, cytokine or genetic profiles of the recruited 
children. The broad repertoire of factors covered in CHARGE study is represented by a 
report on potential effects of traffic-related air pollution in risk of autism (Volk et al., 2011). 
Volk et al. (2011) presented results based on demographic factors of 304 ASD cases, and 
259 typically developing controls, and claimed that mothers with a residence near (< 
309m) to a freeway during the third trimester, or at the time of delivery, had a 2.22-fold 
and 1.86-fold risk, respectively, for ASD in their newborn offspring compared with those 
mothers living further away from freeways or along other roads.  
Recently, King and Bearman (2011) published a study on the socioeconomic status and 
the prevalence of ASD, with a large cohort of nearly 5 million birth records analyzed and 
almost 19,000 established ASD diagnoses in children born in California between 1992 and 
2000. They detected a higher prevalence, and less severe cases of ASD in a community 
composition with higher education and higher property values suggesting that 
neighborhood dynamically interacted with the increase of more, but less severely affected 
cases of ASD. 
 
 
2.8 TREATMENT 
The treatment in autism is targeted at alleviating autistic symptoms and enhancing the 
functional capacity by speech and communication therapy, occupational therapy, 
behavioral training and other methods to improve daily living abilities (Levy et al., 2009).  
There are several clinical protocols of therapies used worldwide and describing them in 
detail is beyond the scope of the present review of the literature. Only a few randomized 
controlled trials on clinical treatments in autism have been carried out.  
Rogers and Vismara (2008) reviewed the effects of different type of therapies in ASD, 
and scored the best category of effectiveness, possibly efficacious, only for three 
randomized controlled interventions. The first of those three trials was a combination of 
parent-training workshops, TEACCH (abbreviated from Treatment and Education of 
Autistic and related Communication-handicapped Children) model speech and language 
therapy and social skills training performed for 28 children with childhood autism for 12 
months (Aldred et al., 2004). The second was a protocol reported by Drew et al. (2002) 
including an intensive discrete trial training of 33h/week along with standard speech and 
language and occupational therapies. The third approach described in the study of Jocelyn 
et al. (1998), with a 12-week intervention targeted not only at the children but also at the 
parents and the childcare workers. However, if one examines the findings in those three 
studies, only Aldred et al., (2004) reported any reduction in autism severity. 
Improvements in speech and communication were common achievements in all three 
studies. 
Most of the pharmacological interventions in autism have been targeted rather towards 
adults rather than at children, and most often on associated behavioral symptoms like 
hyperactivity, aggression and motor stereotypies rather than the core deficits in autism: 
the deficiencies in communication and social interaction (Posey and McDougle, 2001).  
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As the  origin of autistic development remains obscure, it is possible that the 
developmental period for the optimal interventions have already passed at the moment of 
diagnosis and therefore the treatment should be rather targeted at supporting the brain’s 
response to developmental perturbations and enhancing neural plasticity (Bethea and 
Sikich, 2007). 
 
2.8.1 Selective serotonin reuptake inhibitors 
The function of SSRIs is based on inhibiting the reuptake of the neurotransmitter serotonin 
from the synaptic cleft by the SERT molecules present on the presynaptic neuron. 
However, effects on the serotonin receptors and autoreceptors during a long-term 
administration of SSRIs have been described (Gobbi et al., 1997). Furthermore, BDNF and 
its receptor TrkB have been proposed to be involved in the therapeutic actions of 
antidepressant drugs, including the SSRIs (Rantamäki et al., 2007). 
In an open study with fluoxetine treatment in 129 children aged 2 to 8 years with 
childhood autism and continuing the treatment up to 6 years, DeLong et al (2002) reported 
positive effects in an excellent responder group of 17% - these subjects no longer meeting 
the diagnostic criteria of autism - and 52% with a good response showing improved social 
response, emotional stability, attention and awareness of understanding.  Only one-third 
of the patients had a fair or poor response. The mean age of starting fluoxetine was 4½ 
years and the main duration of treatment was 36 months. In that study, a high prevalence, 
in 74% of the families, of either bipolar disorder or major depression, or both, was 
reported. In 85% of cases where children with autism had an excellent/good response to 
fluoxetine treatment, there was a family history of depression or bipolar disorder. In an 
earlier paper examining 37 autistic children DeLong et al. (1998) described more 
specifically the details of the therapeutic response; they reported marked responses within 
2 to 3 weeks after starting medication and especially prominent progress in language 
abilities. They also reported that discontinuation of successful treatment almost invariably 
resulted in regression of both language and behavioral skills, although sometimes the 
regression occurred several months later. 
In a double-blind placebo controlled study of 12-week fluvoxamine treatment in an 
adult population with autism, McDougle et al. (1996) detected a favorable response in 8 of 
15 patients in the fluvoxamine group and none of 15 in the placebo group; the response 
was significant in terms of improved language usage, reduced repetitive thoughts, less 
repetitive or maladaptive behavior, less aggression, and improved social skills. However, 
the same research group could not obtain any clear response with the same treatment 
schedule in a pediatric population with autism, and there were more adverse events in the 
children than encountered in adults (Posey and McDougle, 2001). 
A placebo controlled crossover study of 8-week fluoxetine treatment focused on the 
repetitive behavior in children and adolescents of 5 to 17 years of age Hollander et al., 
2005). This revealed a significant decrease of symptoms on a Children’s Yale-Brown 
Obsessive-Compulsion Scale and a trendtowards a reduction of global autism severity 
(Hollander et al., 2005). The side effects reported in this study were interesting; only 
anorexia and drowsiness were experienced more often during fluoxetine vs. placebo (15% 
vs. 11% and 18% vs. 11%, respectively) but anxiety, insomnia, agitation, diarrhea, weight 
gain or respiratory infections  occurred with equal frequency, or were even more frequent 
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in the placebo group. 
On the other hand there have been studies with SSRI therapy with less favorable 
results. In a randomized, blinded, multicenter study determining efficacy and safety of a 
12-week citalopram treatment for repetitive behavior in 149 children and adolescents with 
ASD, no differences were found in the rate of positive responses between the citalopram-
treated and the placebo groups (King et al., 2009). 
Fluoxetine treatment has also been tested in an experimental model of autism i.e. a 
mouse strain presenting autistic-like behavior; sociability in the mice increased after 
administration of fluoxetine, but not after risperidone, an atypical antipsychotic agent 
(Chadman, 2011). 
  
2.8.2 Atypical antipsychotics 
The first generation of antipsychotic drugs (for instance chlorpromazine and 
haloperidole), or the typical antipsychotics, are considered to exert their effects through 
their potent dopamine type 2 receptor antagonism. However, these drugs may cause 
severe adverse effects, especially extrapyramidal symptoms, which can be irreversible in 
some cases. The second generation of antipsychotic drugs (e.g. risperidone and 
aripirazole), more commonly called the atypical antipsychotics, bind less effectively to the 
dopamine 2 receptors but have also some affinity for the serotonin type 2A receptors, 
having an antagonist effect. The abovementioned distinctions are believed to explain the 
milder spectrum of adverse events in the atypical antipsychotics as compared with the 
first generation antipsychotics (Seeman, 2002).   
In autism, antipsychotics have been used to alleviate behavioral and mood disturbances 
such as aggression, agitation, and irritation. However, the benefit from the first generation 
antipsychotics has been limited by the relatively high frequency of adverse reactions 
(Posey et al., 2008). Risperidone, a second generation “atypical” antipsychotic, was the first 
drug to be used for the treatment of severe behavioral symptoms in autistic children and 
adolescents to be approved by the Food and Drug Administration in 2006 in the United 
States, and in 2009 also aripirazole was approved for the same indication.  at present, 
neither of these drugs has gained official acceptance for the abovementioned indication in 
Finland, or elsewhere in the European Union. However, they have been approved for use 
in severe behavioral problems in mental disorders and in mentally retarded patients, aged 
from 5 years, or for schizophrenic patients, aged from 15 years.  
McCracken et al. (2002) conducted a randomized study with 101 autistic children and 
reported that risperidone relieved aggression and other unwanted behaviors after 8 weeks 
of therapy. A positive response was reported in 49 children which was a statistically 
significant result. The favorable effects remained after 6 months in two-thirds of the 
patients with a good response rate at the 8-weeks’ check-point.  
In another study, after  3-months’ therapy with risperidone, an increase in regional 
blood flow in frontal and prefrontal regions was detected, in parallel with a clinical 
improvement, in 11 autistic children aged 6 to 7 years (Ozdemir et al., 2009). 
Another drug in this category, olanzapine has been reported to show improvement in 
core social and language impairment in pervasive developmental disorders, the broader 
aspect of the autism spectrum (Potenza et al., 1999, Hollander et al., 2006).  
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2.8.3 Other medications 
Several other drugs with different mechanisms of action have been studied in autism, 
including, but not limited to, anticonvulsants, stimulants, alpha agonists and 
acetylcholine-esterase inhibitors.  
The effect of anticonvulsant drugs on the autistic symptoms has been studied in autistic 
patients with or without concomitant epilepsy. Several antiepileptic drugs, including 
carbamazepine, valproic acid, lamotrigine and gabapentin have effects on serotonergic 
tone through several molecular mechanisms (Di Martino and Tuchman, 2001). 
Lamotrigine, an anticonvulsant attenuating glutamate release, has been reported to relieve 
the autistic symptoms of autistic patients with epilepsy (Uvebrant and Bauziene, 1994) but 
this finding has not been confirmed (Belsito et al., 2001). With the antiepileptic agent 
levetiracetam, a reduction in the amount of behavioral disturbances has been detected by 
some researchers (Rugino and Samsock, 2002) but others have not found any benefits 
(Wasserman et al., 2006). All these studies have been limited by small group sizes and also 
in the duration of the treatment.  
As hyperactivity and inattention are commonly associated behaviors in autistic 
individuals it is not surprising that stimulants, with have gained status in attention deficit 
hyperactivity disorder (ADHD), have also been widely studied in autism. 
Methylphenidate is a reuptake inhibitor of the neurotransmitters dopamine and 
norepinephrine, increasing their availability at central synapses in brain. The clinical 
response to methylphenidate in ADHD patients has been linked to high striatal DAT 
availability before treatment, followed by a decrease in DAT availability during treatment 
(Krause et al., 2005). Recently, Jahromi et al. (2009) presented a study report about a  4-
week randomized, double-blind crossover trial with methylphenidate in 33 children with 
ASD, of mean age of 7 years. They detected a significant positive effect on joint attention, 
self-regulation, and regulating affective state, while side-effects were rather rare (Jahromi 
et al., 2009).  
Two alpha-2 adrenergic agonists, clonidine and guanfacine have been used to treat 
inattention, hyperactivity and aggression in autism but the benefits have been eroded by 
the high incidence of adverse events (Scahill et al., 2006). 
Some preliminary studies in autistic patients have been performed with the 
acetylcholine-esterase inhibitors, donepezil and galantamine, but the results have been 
inconsistent; some improvements in the core social and language impairments were 
reported (Nicolson et al., 2006, Handen et al., 2011). 
In Smith-Lemli-Opitz syndrome, a genetic disorder with a deficiency in cholesterol 
synthesis and which bears a high relationship to autism, early cholesterol supplementation 
started before the age of 5 years has been reported to reduce the risk of autism, but not if 
supplementation occurred later (Tierney et al. 2001). 
In an experimental study, another potential treatment has been introduced in a mouse 
model of fragile X syndrome; reducing levels of striatal-enriched tyrosine phosphatase, an 
enzyme modulating synaptic plasticity and neuronal function, was associated with 
increased social behavior in the affected mice (Goebel-Goody et al., 2012). Furthermore, in 
a drosophila model of fragile X syndrome, administration of a glutamate receptor 
antagonist, methyl-6-phenylethynyl-pyridine has been reported to reverse abnormalities 
in brain structure and behavior, but only if given during early development (McBride et 
al, 2005). These findings are interesting with respect to autism, since in humans with 
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fragile X syndrome, the prevalence of ASD is increased (see Chapter 2.3). 
 
 
2.9 PROGNOSIS 
Autism and autism spectrum disorder are generally assumed to be lifelong conditions 
although the severity and the repertoire of the symptoms may change with time. The time 
or type of the onset of the symptoms does not appear to make any difference in later 
functioning or to the prognosis of the subject (Shumway et al., 2012). 
In a recent review of studies investigating the course and prognosis of autism spectrum 
disorder, predictors of better outcome were normal intelligence level (IQ above 70), early 
communication and language abilities, especially spoken language at preschool age, 
verbal and nonverbal imitation skills and early joint attention skills, whereas the co-
existence of genetic syndrome, mental retardation and epilepsy were unfavorable 
predictive factors (Helt et al., 2008). 
In another study, there was no correlation between the age of onset of autistic 
symptoms and the clinical manifestation at age of 18 years in 38 autistic individuals with 
the historical diagnosis of autism who were followed by Tolbert et al. (2001), and 
furthermore no differences in IQs, proportion of males or need for institutional care was 
detected either. 
 Baghdadli et al. (2007) evaluated 219 children with childhood autism and atypical 
autism, and found that ability to speak at the age of 5 years predicted significantly the 
evolution of daily living skills in the next 3 years: those with speech at 5 years of age 
developed in their daily living skills but those without speech displayed a relative 
regression in skills. 
Sigman and McGovern (2005) reported a follow-up of 48 autistic children with autism 
from preschool age to late adolescence measuring cognitive skill, language abilities and 
nonverbal communication. The improvement in cognitive and language skills was more 
evident in individuals with high functioning autism than in those with low functioning 
autism, and progress was more stable through the years in those with high function 
autism. 
Lord et al. (2006) reported a 7 year follow-up of the stability of the autism spectrum 
disorder diagnoses established at 2 years of age. Of the children with an original diagnosis 
of childhood autism, 83 of the 84 still remained in the autism spectrum disorder at the age 
of 9 years. Those 46 children with an original diagnosis of pervasive developmental 
disorder not otherwise specified showed more variation at age of 9 years: 27 were best-
estimated as having childhood autism, 14 pervasive developmental disorder not otherwise 
specified, and 5 no longer met any of the autism spectrum disorder criteria (Lord et al., 
2006).  
Cederlund et al. (2008) followed 76 males with Asperger syndrome and 77 autistic 
males for more than 5 years after the original diagnosis with the individual having been 
aged 16 to 38 years at the time of follow-up. They found that 8 of the patients with 
Asperger syndrome and one with autism no longer met the diagnostic criteria for autism 
spectrum disorder. Moreover, there was a great difference in the overall outcome between 
the two groups: at the age of 23 years or older, 64% in the Asperger syndrome group were 
living independently, but only 8% in the autistic group (Cederlund et al., 2008).  
Szatmari et al. (2009) followed two patient groups, one with high functioning autism, 
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the other with Asperger syndrome from childhood to adolescence, and found that 
socialization, communication and daily living skills were better in the Asperger group 
already at ages of 4 to 6 years, and the difference remained significant at the end of the 
follow-up at 18 years of age.   
Danielsson et al. (2005) followed up 120 individuals with autism from childhood up to 
ages ranging from 17 to 40 years, and reported epilepsy in 48% of autistic patients with 
severe mental retardation, in 20% of those with mild or moderate mental retardation, and 
in 16% of those with no mental retardation. However, the number of those with no mental 
retardation was very low in that study, only 6 subjects (Danielssson et al., 2005). In a 
recent study with 150 young adults with autism, Bolton et al. (2011) reported that 22% of 
patients were suffering from epilepsy, but those with severe or profound mental 
retardation were excluded. Epilepsy was associated with female gender, intellectual 
disability and poorer verbal skills, and the mean age of the onset of epilepsy was 13 years 
(Bolton et al., 2011).  
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3 Aims of the study 
 
Neuronal growth factors and monoaminergic neurotransmission have attracted attention 
in autism because of the findings of abnormalities in growth and development of brain 
structures, and alterations in the serotonergic system. Experimental studies have pointed 
to an association between the growth factors and monoaminergic neurotransmission, and 
that certain antidepressant drugs might act on that interaction. The aim of this study was 
to investigate the possible correlations of growth factors and monoaminergic 
neurotransmission in autistic children and adolescents, and to evaluate the efficacy of 
serotonin reuptake inhibition on the core symptoms of autism. The specific aims of the 
present study were: 
 
1. To measure IGF-1 and IGF-2 concentrations in serum and in CSF, and to evaluate 
correlations between those parameters and head circumference in autistic children, 
aged 2 to 16 years, as compared with healthy control children. (Publication I) 
 
2. To measure SERT and DAT binding capacity in the brains of autistic children, aged 
5 to 16 years, by SPECT and to compare the results with those of comparison 
children, aged 7 to 12 years, with non-autistic neurological symptoms. (Publication 
II) 
 
3. To measure effects of a six-month treatment with fluoxetine, an SSRI drug, on 
concentrations of IGF-1 and BDNF in serum and in CSF, on SERT and DAT 
binding capacities by SPECT measurements, and on clinical response as assessed 
by the Autism Treatment Evaluation Checklist (ATEC) in autistic subjects, aged 5 
to 16 years. (Publications III and IV) 
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4 Subjects and methods 
 
4.1 ETHICS 
The study protocol was approved by the Research Ethics Committee of the Hospital 
District of Northern Savo, Kuopio, Finland, and the Finnish Medicines Agency was 
notified. Written informed consent was obtained from the parents of the autistic subjects. 
For the BDNF components of the study, the protocol was explained to the control children 
and their parents and written informed consent was obtained. Those children able to 
understand the protocol gave assent.  
The protocol for serum and CSF sample analysis of BDNF was also approved by the 
Johns Hopkins Medical Institutions’ Institutional Review Board. 
 
4.2 SUBJECTS 
4.2.1 Autistic children 
 
A total of 26 children and adolescents with childhood autism were recruited into the 
study. The flow chart of the patients is presented in Fig 4.1. No individuals with Asperger 
syndrome or pervasive developmental disorder not otherwise specified were included. 
None of the individuals with autism had either tuberous sclerosis, fragile X syndrome, or 
any major chromosomal defect. They did not have a history of perinatal asphyxia, severe 
infections of the central nervous system, nor a head injury requiring medical care. MRI of 
the brain was normal in all individuals. Autistic patients did not receive any medication 
with effects on serotonin and/or dopamine metabolism during the study or during the 
preceding 3 years. 
The main study took place in the Department of Pediatrics, Unit of Child Neurology, 
Kuopio University Hospital, Kuopio, Finland, and 15 children and adolescents were 
recruited from the Northern Savo Province of Finland. The information of the children 
with a diagnosis of childhood autism, and aged less than 16 years by the end of year 2003 
was gathered from the data system of Kuopio University Hospital, Kuopio, Finland. The 
families with autistic children were first contacted by phone, and then a personal meeting 
was arranged with the investigator (IM) for provision of more detailed information. These 
contacts were made for families with a total of 25 autistic children from 5 to 16 years of 
age. One family had 3 autistic children, in other families there was only 1 individual with 
childhood autism. Finally 15 families, with 1 autistic child in each, accepted to participate, 
and those 15 children and adolescents, aged from 5 to 16 years (mean age 8 years 8 
months; 14 males, 1 female), were recruited into the study. 
Families refusing to take part in the study had 10 children from 7 to 13 years of age 
(mean age 10 years; 6males, 4 females). The 3 siblings with autism in the same family were 
among those who refused to participate. 
In addition, 11 autistic children from Southern Finland had been recruited earlier at the 
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Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, 
Finland. These 11 children were included in the first phase of the study concerning the 
measurements of HC and IGF-1. This group of autistic children has been examined earlier 
in a comparison with 11 children with severe neurological disorders; those results have 
been published in a report of Vanhala et al. in 2001. 
Only those 15 individuals with autism recruited in Kuopio University Hospital 
participated all the phases of HC, IGF-1, IGF-2, BDNF, SERT, and DAT investigations - 
presented in detail later in this chapter - prior to fluoxetine treatment.  
The diagnosis of the patients with autism in the present study was based on repeated 
multiprofessional studies, and the criteria of autism were as defined by ICD-10 (World 
Health Organization, 1993) and DSM-IV-TR (American Psychiatric Association, 2000) 
criteria. 
In the 15 children and adolescents with autism recruited at Kuopio, the investigations 
prior to treatment included also CARS evaluation (Schopler et al., 1980) for the severity of 
autism and a psychological study conducted with the Leiter method (Roid and Miller, 
1997) to define the intellectual capacity of the subjects. Other commonly used autism 
assessment instruments such as Autism Diagnosis Interview-Revised (Lord et al., 1994), or 
Autism Diagnostic Observation Schedule (Lord et al., 2000) were not utilized in the 
present study because the use of these methods had not yet been established in Finland. 
However, the basic information received from CARS and ICD-10 criteria were considered 
as being sufficient for the needs of the present study. 
Into the fluoxetine treatment phase, 14 subjects with autism of the Kuopio study group 
went on; one male subject withdrew because of moving away from the province.  
There was one drop-out during the fluoxetine treatment period; an autistic male did not 
finish this phase due to family request. The reason for withdrawal of consent was a family 
matter, not dependent on the efficacy or side-effects of the medication. 
The phases of the study with autistic children and adolescents in each step are shown in 
Figure 4.1. 
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Figure 4.1. Flow chart of the autistic subjects in the study. 
 
4.2.2 Control children 
A total of 41 children and adolescents served as controls in the different study stages. 
In the HC, IGF-1 and IGF-2 parts of the study 16 age-matched subjects were recruited from 
children and adolescents admitted to Kuopio University Hospital for surgery on the lower 
part of the body, to be performed under spinal anesthesia. The control children without 
autism or any other neuropsychiatric disorder did not have any symptoms or signs of 
nutritional, metabolic or endocrine disorder that might have influenced the IGF 
concentrations. The age of these control children was from 1 year to 15 years (mean 7 years 
4 months; 8 males, 8 females), and they had following conditions requiring surgery; 
IGF-1, IGF-2 and Head 
Circumference 
n=25 
(Publication I) 
IGF-1, BDNF, SERT, DAT, ATEC 
n=13 
(Publications III and IV) 
Withdraw consent             
n=1 
Lost to follow-up  
n=1 
Helsinki Autistic Cohort 
n=11 
Kuopio Autistic Cohort 
n=15 
SERT, DAT and BDNF 
n=15 
(Publication II) 
Fluoxetine treatment 
n=14 
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herniotomy (n=6), orthopedic or traumatologic operations (n=6), urogenital procedures 
(n=4). 
In the SPECT study, the comparison children were selected from a previous study 
(Riikonen et al., 2005). These 10 comparison children were examined originally due to 
their neurological symptoms, excluding autism spectrum disorders or intellectual 
disability. These children, aged 7 to 14 years (mean age 9 years 10months; 5 males, 5 
females), had the following symptomatic diagnoses which warranted a SPECT 
examination: tremor (n=3), cephalalgia (n=2), tremor and cephalalgia (n=1), epilepsy (n=1), 
unexplained odd feeling (n=1), motor disturbance (n=1), and long-lasting tiredness (n=1). 
In the BDNF studies, 15 neurologically healthy children were recruited from those 
admitted to hospital for lower body surgery to be performed under spinal anesthesia. 
These children without autism had no nutritional, metabolic or endocrine disorders that 
might have influenced the BDNF concentrations. These control children, aged from 4 to 15 
years (mean age 8 years 8 months; 13 males, 2 females), had been admitted for the 
following indications for surgical procedures: inguinal herniotomy (n = 6), orthopedic 
procedures (n = 6), and operations of urogenital system (n = 3). 
The phases of the study in aspect of the control children are demonstrated in a flow 
chart in Figure 4.2. 
 
 
 
 
 
 
 
 
 
Figure 4.2. Flow chart of the control subjects in the study. 
 
  
4.3 METHODS 
 
4.3.1 Head circumference  
Head circumference was measured at the time of sample collection for the IGF-studies. HC 
measures were expressed as z scores from the mean HCs of age and sex-matched 
individuals from the general Finnish population.  
Controls 
n=41 
Children for IGF-1, IGF-2 
and head circumference 
studies   n=16 
(Publication I) 
Children for SERT and 
DAT studies 
n=10 
(Publication II) 
Children for BDNF 
study 
n= 15 
(Publication III) 
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4.3.2 IGF-studies 
 
Serum and CSF samples of children with autism were drawn when the patients were 
slightly sedated (with intravenous midazolam 0.1mg/kg and propofol/thiopental 1-
2mg/kg) for the SPECT study and from the comparison children during the spinal 
anesthesia performed for the surgery on the lower part of the body. 
The serum and CSF samples were frozen and stored until analysis. The concentration of 
IGF-1 and IGF-2 were determined by a radioimmunoassay method (Mediagnost GmbH, 
Reutlingen, Germany) in the Helsinki University Central Laboratories. 
 
4.3.3 BDNF studies  
 
Serum and CSF samples for BDNF studies were collected from the autistic subjects during 
sedation required for the SPECT. In the comparison children similar samples were drawn 
during the lumbar puncture performed as part of the spinal anesthesia for the lower body 
surgery. The samples were frozen immediately and stored at -70°C until analysis. BDNF 
analyzes were assayed by the sandwich-enzyme-linked immunosorbent assay method 
using a commercial kit for human BDNF (Chemicon, Temecula, CA, USA) following the 
manufacturer´s protocol and including a range of subject sample and technical controls. 
The sensitivity of the method is 7.8 pg/mL. The BDNF analyzes were performed in the 
Kennedy Krieger Institute, Baltimore, MD, United States of America. 
 
4.3.4 SPECT imaging 
 
Serial SPECT scans were obtained at 15 minutes, and at 6 and 24 hours after intravenous 
injection of 80 to 150 MBq of iodine-123 labelled N-(2-fluoroethyl)-2b-carbomethoxy-3b-(4-
iodophenyl)-nortropane, ([123I] nor-beta-CIT) (MAP Medical Technologies OY, Tikkakoski, 
Finland) on a dedicated Siemens MultiSPECT 3 gamma camera with fan-beam collimators 
(Siemens Medical Systems Inc., Hoffman estates, USA). The SPECT scans were decay-
corrected, reconstructed with Butterworth-filtered back-projection and attenuation-
corrected with Chang’s algorithm (Cμ =0.11 cm-1). Regions of interest were midbrain, 
temporal lobes, medial frontal cortex (MFC), and striatum. The cerebellum served as a 
reference region (i.e. a region with non-specific and free binding). The specific values of 
ligand binding in mL/mL for SERT (midbrain, MFC, and temporal lobes) and DAT 
(striatum) were calculated using a graphical plot. The slope of this plot is equal to the 
distribution volume ratio: (Region – Cerebellum) / Cerebellum. Radiation exposure to the 
participants was 4–5mSv (effective dose). 
Sedation was required for the children with autism and adolescents, because they were 
unable to remain still during the 30 minutes of the SPECT scan. For the 15 minutes and 24 
hours SPECT scan the children with autism were given per oral sedation with midazolam, 
at a dose of 0.3–0.5mg/ kg, (max. 7.5mg) (Dormicum® fluid for injection, 5mg / mL, Roche, 
Espoo, Finland). For the 6 hour SPECT scanning, intravenous sedation with midazolam 
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(0.05–0.1mg/ kg), propofol (1–2mg/ kg) and thiopental (1–2mg/ kg) was given. For the non-
autistic individuals, the SPECT scans were performed without sedation or anesthesia, 
because the SPECT scan was done for clinical reasons and no lumbar puncture was 
performed.  
 
4.3.5 Fluoxetine therapy  
 
Fluoxetine (Seromex® 10 mg soluble tablets, Ratiopharm, Ulm, Germany) was given once 
daily in the morning. The trial was begun with a dose of 5 mg, which was raised by 5 mg 
(in children) or 10 mg (in adolescents) every 2 weeks until the highest tolerated dose or a 
maximum dose of 1 mg/kg or 40 mg total was reached. Children continued to receive 
special education and other interventions (i.e., speech and language therapy, occupational 
therapy) without any modification during the treatment trial. 
Therapeutic doses ranged from 10–40 mg/day (0.4– 0.9mg/kg/day, mean 
0.53mg/kg/day). The pharmacotherapy was given for 6 months, after which fluoxetine was 
discontinued by decreasing the dose gradually over a period of 2 to 4 weeks. Following 
this, all patients had a 2-month wash out period before SPECT scanning to exclude any 
acute effect of fluoxetine on SERTs. 
 
4.3.6 Evaluation of clinical response 
 
The clinical response to fluoxetine was evaluated with a follow-up checklist based on the 
Autism Treatment Evaluation Checklist (ATEC), an instrument developed by Rimland 
and Edelson in the Autism Research Institute, San Diego, CA, USA in 2000 and which is 
published in the Internet as for free use for clinical and research purposes (Website 
address updated in April 2012: http://www.autism.com/index.php/ind_atec_survey). 
There appeared to be no Finnish translation for the ATEC available, therefore for the 
purpose of the present study a translation was made by the first author (IM), and it was 
checked by the senior researcher (RR). 
ATEC has four sections with multiple statements concerning the individual 
characteristics or abilities:  
 
ATEC 1: 14 items on speech, language and communication 
ATEC 2: 20 items regarding socialization 
ATEC 3: 18 items on sensory or cognitive awareness 
ATEC 4: 25 items on health, physical condition, or behavior 
 
The adverse effects of the fluoxetine treatment were evaluated by including 12 
questions in ATEC 4. These questions were selected considering the generally known 
adverse events of SSRI in children, adapted from a list from the British Columbia’s 
Children’s Hospital, Vancouver, Canada (Website address updated in April 2012: 
http://www.bcchildrens.ca/NR/rdonlyres/25643C99-5CE2-48F4-9757-
0DDB45EED706/42895/SSRIteachingsheet1pageJun20091.pdf).  
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In the original ATEC, there are three alternative choices of answers for each phrase in 
ATEC 1, 2 and 3 (not true/not descriptive, somewhat true/somewhat descriptive, or very 
true/very descriptive) and four choices in ATEC 4 (not a problem, minor problem, 
moderate problem, or serious problem). In the present study, an adapted scale from 1 to 5 
was employed in, which meant that the endpoint values were given the following 
definitions: 1= the statement/observation does not match the child at all, 5 = the 
statement/observations match the child perfectly.  
Baseline information was gathered during an interview with the parents by the 
investigator (IM) by filling in the ATEC checklist together, this arrangement provided the 
parents the opportunity to ask clarifying questions if needed. During the treatment period, 
the parents reported the status every 1-2 weeks by filling out the checklist themselves.  
They were encouraged to give more detailed information written in their own words if 
needed and they were advised to contact the investigators whenever they suspected drug 
intolerability or adverse effects in their child. After the treatment period, in the follow-up 
visit, the checklist was again filled out by the parents and the investigator together. 
 
Table 4.1. Autism Treatment Evaluation Checklist - adapted version. 
The additive statements or findings considering the possible adverse effects of fluoxetine are  
ATEC 4 items 3, 7, 8, 9, 13, 14, 23, 24, 25, 26, 27 and 28. 
ATEC 1. Speech/ Language/ Communication   
1. knows own name 8. can use sentences with 4 or more words 
2. responds to ”no” or ”stop” 9. explains what he/she wants 
3. can follow some commands 10. asks meaningful questions 
4. can use one word at a time 11. speech tends to be meaningful/ relevant 
5. can use  2 words at a time 12. often uses several successive sentences 
6. can use 3 words at a time 13. carries on fairly good conversation 
7. knows 10 words or more 14. has normal ability to communicate for his/her age 
 
ATEC 2. Sociability 
1. seems to be in a shell – you cannot reach him/her 11. dislikes being held/cuddled 
2. ignores other people 12. does nor share or show (things meaningful for him/her, e.g. 
3. pays little or no attention when addressed 13. does not wave ”bye bye” 
4. uncooperative and resistant 14. disagreeable/ not compliant 
5. no eye contact 15. temper tantrums 
6. prefers to be left alone 16. lacks friends/ companions 
7. shows no affection 17. rarely smiles 
8. fails to greet parents 18. insensitive to other’s feelings 
9. avoids contact with others 19. indifferent to being liked 
10. does not imitate 20. indifferent if parent(s) leave 
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ATEC 3. Sensory/ Cognitive awareness 
1. responds to own name 10. aware of environment 
2. responds to praise 11. aware of danger 
3. looks at people and animals 12. shows imagination 
4. looks at pictures (and TV) 13. initiates activities 
5. does drawing, coloring, art 14. dresses self 
6. plays with toys appropriately 15. curious, interested 
7. appropriate facial expression 16. venturesome - explores 
8. understands stories on TV 17. ”tuned in” – not spacey 
9. understands explanations 18. looks where others are looking 
 
ATEC 4. Health/ Physical/Behavior/Adverse Effects 
1. bed-wetting 20. destructive 
2. wets pants/ diapers 21. sound-sensitive 
3. other urinary problems 22. anxious /fearful 
4. soils pants/diapers 23. cramps or tics 
5. diarrhea 24. tremble or shakes 
6. constipation 25. headache 
7. stomach ache 26. sweating 
8. sickness 27. palpitation 
9. sleeplessness 28. eczema or rash 
10. other sleep problems 29. unhappy / crying 
11. eats too much 30. seizures 
12. eats too little 31. obsessive speech 
13. loss of weight too much 32. rigid routines 
14. increase of weight too much 33. shouts or screams 
15. extremely limited diet 34. demands sameness 
16. hyperactive 35. often agitated 
17.lethargic 36. not sensitive to pain 
18. hits or injures self 37. “hooked” or fixated on certain objects / topics 
19. hits or injures others 38. repetitive movements  (stimming, rocking, etc.) 
 
 
 
4.4 STATISTICS 
 
The data of the present study are based on a total of 26 patients with autism who were 
available for this study. In the Kuopio cohort parents of 25 autistic children were asked for 
consent, but 10 declined to allow their children to participate. In order to validate the data 
obtained from autistics children, a comparison group of 16 age-matched children without 
autistic symptoms was enrolled to compare the correlations of HC measurements and 
concentrations of IGFs and BDNF in autistic children. For the SERT and DAT binding 
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capacity, the data of 15 patients with autism was compared with that of 10 age-matched 
children without autism. No formal sample size calculation was performed but these 
numbers of autistic children and controls were considered as providing sufficient data for 
the purposes of this study.  
Before performing the statistical calculations, the continuous variables were tested for 
normal distribution with the Kolmagorov-Smirnov test. For normal distributed data, the 
unpaired Student’s t-test was applied. For non-normally distributed data, Mann-Whitney 
U test, and Wilcoxon signed ranks test were used. To analyze the differences for the 
frequency data and the simultaneous group effects the Pearson’s χ2 test and regression 
analysis were used. 
The data were stored and the calculations were made using the Statistical Package for 
Social Sciences software (SPSS for Windows 17.0, SPSS Inc., Chicago, USA). In all statistical 
tests, a two-tailed p-value of less than 0.05 was considered statistically significant. 
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5 Results 
 
5.1 HEAD GROWTH AND INSULIN-LIKE GROWTH FACTORS IGF-1 AND 
IGF-2  
 
5.1.1. Prior to treatment (Publication I) 
 
In this present study, none of the autistic subjects or the controls had either macrocephaly 
or microcephaly, i.e. the relative HC score was not beyond the borders of ± 2SD, at the 
moment of the study. The mean HC was +0.3 SD in the groups of both autistic and control 
children.  
Detailed data about head growth from birth until the date of the present study was 
available in 14 out of 15 autistic children of the Kuopio cohort. The growth pattern in 
infancy showed an acceleration of head growth from birth to 3 months of age in 10 infants 
out of 14. Furthermore, 11 out of 14 had their peak relative HC before 6 months of age, and 
2 of them had a single HC measurement with a relative HC score above +2 SDs (Above-
mentioned details are not presented in the Publications). 
The mean concentration of CSF-IGF-1 (0.41μg/L [SD 0.18]) in 25 patients with autism 
was significantly lower than that in 16 patients in the control group (0.58μg/L [SD 0.27]; 
p=0.02, t-test). There was a significant correlation between the CSF-IGF-1 concentration 
and age both in the children with autism (r=0.68, p=0.002) and in the age-matched group 
(r=0.56, p=0.025; Fig. 5.1). A post hoc analysis revealed that in the children with autism 
who were less than 5 years of age (n=11) the mean CSF-IGF-1 concentration (0.27μg/L [SD 
0.10]) was significantly lower than that in their age-matched control group (n=5; 0.44 μg/L 
[SD 0.15]; p=0.014).However, in the children who were 5 years of age or older, there was 
no difference in the mean CSF-IGF-1 concentration of the children with autism (n=14; 
0.52μg/L [SD 0.16]) in comparison with the control group (n=11; 0.64μg/L [SD 0.29]; 
p=0.20). 
The CSF-IGF-1 concentrations correlated significantly with head circumferences in the 
patients with autism (r=0.48, p=0.014) but not with those of the control group (r=0.06, 
p=0.85; Fig. 5.2).  
There was no difference between the autistic and control groups in CSF-IGF-2 
concentration; the mean was 19.1μg/L (SD 3.1) in 25 patients with autism and 20.5 μg/L 
(SD 4.4) in 16 patients in the control group (p=0.33). There was no correlation between the 
CSF-IGF-2 concentration and age in the group with autism (r=0.15, p=0.60) but a 
significant correlation was seen in the control group (r=0.55, p=0.027). There was no 
difference between the two groups in the correlation with head circumference and CSF-
IGF-2 concentration (r=0.53 and r=0.56, respectively). 
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Figure 5.1. Concentrations of cerebrospinal fluid insulin-like growth factor-1 (CSF IGF-1) 
and age in children with autism (●; n=25), and their age-matched controls (○; n=16). 
 
 
Figure 5.2. Concentration of cerebrospinal fluid insulin-like growth factor-1 (CSF IGF-1) with head 
circumference (SD) in children with autism (●; n=25), and in their age-matched controls (○; n=16). 
 
5.1.2 After fluoxetine treatment (IV) 
Cerebrospinal fluid IGF-1 concentration increased from baseline (CSF-IGF-1 mean 0.53 
pg/mL, SD 0.18 pg/mL) to the end of fluoxetine treatment (mean 0.68pg/mL, SD 0.20 
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pg/mL, p= 0.003 paired samples t-test) in the autistic children. There was no significant 
correlation detected between the IGF-1 concentration and the clinical response (p=0.86). 
CSF-IGF-2 concentrations were not investigated after fluoxetine treatment. 
 
5.2 BRAIN DERIVED NEUROTROPHIC FACTOR 
5.2.1 Prior to treatment (III) 
There was no group difference in serum BDNF concentrations between the autistic 
subjects (range <7.8−17149 pg/mL, [mean 6330, SD 6591 pg/mL]) and the control group (n = 
15) (range 4575–14927 pg/mL, [mean 9652, SD 3223 pg/mL]) (p = 0.08). However, there was 
a bimodal distribution of BDNF concentration within the autistic group; subgroups had 
either a remarkably low concentration (n=8, mean 1497, SD 1651 pg/mL) or a concentration 
which was higher than the mean of the controls (n=5, mean 14062, SD 2026 pg/mL) (Table 
5.1).  
 
Table 5.1. Serum brain derived neurotrophic factor concentration and serotonin transporter 
binding in medial frontal cortex and midbrain, as compared with clinical response after fluoxetine 
treatment in autistic children. 
Age 
(years) 
Serum Brain Derived 
Neurotrophic Factor (pg/mL) 
Serotonin transporter binding capacity 
(mL/mL) 
Medial frontal cortex Midbrain 
Prior to 
treatment 
After 
treatment 
Prior to 
treatment 
After 
treatment 
Prior to 
treatment 
After 
treatment 
Good clinical responders *      
6 2,954 711 0.05 0.12 1.30 1.11 
6 12,837 1,290 0.28 0.15 1.34 1.25 
8 17,148 5,557 0.08 0.33 1.07 1.25 
11** 11,760 1,728 0.11 0.06 1.00 1.02 
13 1,375 1,229 0.23 0.29 1.07 1.10 
16 14,320 1,821 0.16 0.20 1.09 1.17 
Poor clinical responders *      
5 56 10,390 0.20 0.19 1.18 1.49 
5 14,247 13,652 0.06 0.15 1.09 1.15 
5 556 5,283 0.32 0.34 1.11 1.32 
5 < 8 2,909 0.24 0.19 1.24 1.01 
8 1,941 1,229 0.08 0.14 1.02 1.11 
12 379 10,035 0.08 0.22 1.06 1.14 
13 4,709 5,374 0.07 0.29 1.07 1.35 
 
* According to Autism Treatment Evaluation Checklist Section 2 (ATEC 2); socialization 
** Female autistic patient, all other are males   
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5.2.2 After fluoxetine treatment (III) 
 
In autistic individuals, after fluoxetine treatment, the BDNF concentration was lower 
(range 711–13652 pg/mL, [mean 4891, SD 4194 pg/mL]) than that determined before the 
treatment, but the change was not significant statistically (p=0.44). BDNF concentration 
decreased in eight patients and increased in five, eliminating the bimodality observed 
prior to treatment. 
 
5.3 SEROTONIN TRANSPORTER 
 
5.3.1 Prior to treatment (II) 
 
SERT binding capacity was significantly lower in autistic children in MFC (p=0.001, 
Mann–Whitney U test; Fig. 5.3) and in midbrain (p=0.02) than in the controls (Table 5.2). 
The differences between individuals with autism and the control group in SERT binding 
capacity in midbrain and in MFC remained significant also when adjusted for age. The 
regression coefficients were 0.11 units (95% CI: 0.03–0.20, p=0.014) and 0.18 units (95% CI: 
0.10– 0.26, p<0.001) for SERT binding capacity in midbrain and in MFC respectively. 
After the correction due to the assumed effect of sedation of the patients with autism 
during the SPECT scans, the difference in SERT binding remained significant in MFC 
(p=0.002, Mann–Whitney U test), but no longer in the other areas. 
 
Table 5.2. Serotonin transporter (SERT) binding in different brain areas in 15 children with autism 
and in 10 control children. 
Group Age 
(years) 
SERT (mL/mL) 
  Midbrain Temporal 
Left 
Temporal 
Right 
Medial 
frontal cortex 
Autistic children      
Mean (SD) 8.7 (3.8) 1.11 (0.09) 0.20 (0.09) 0.20 (0.06) 0.14 (0.10) 
      
Controls      
Mean (SD) 9.8 (2.7) 1.22 (0.12) 0.29 (0.13) 0.29 (0.12) 0.32 (0.08) 
      
p-value  0.02 0.23 0.09 0.001 
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Figure 5.3. Serotonin transporter (SERT) binding in medial frontal cortex and age in patients with 
autism (•; n=15) and in control group (○; n=10).  
 
5.3.2 After fluoxetine treatment (III) 
 
After the fluoxetine treatment, there was an increased SERT binding capacity in both the 
midbrain and in the medial frontal cortex, but the change was not statistically significant 
(p=0.09 in both areas) (Table 5.1). There were no significant correlations between SERT 
binding capacity in the abovementioned areas and BDNF concentrations, either before or 
after the treatment. 
 
 
5.4 DOPAMINE TRANSPORTER 
5.4.1 Prior to treatment (II) 
The baseline results of DAT binding detected no significant group difference between the 
autistic children and the control children (p=0.21). However, there was a trend towards a 
negative correlation between DAT binding capacity and age in the autistic subjects, 
whereas in the control group the correlation had a positive trend (Figure 5.4). 
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Figure 5.4. A divergent correlation between striatal dopamine transporter binding capacity and 
age in the autistic children (●) and control children (○). 
 
5.4.2 After fluoxetine treatment (IV) 
Six clinically good responders exhibited a significant decrease in striatal DAT binding (-
0.25 mL/mL, SD 0.20, p<0.05) after the fluoxetine treatment. The other autistic children had 
a trend to an increase in both DAT binding and serum BDNF concentration after the 
treatment. 
 
 
5.5 CLINICAL FINDINGS (III) 
 
Before initiating the present study, the completion of the CARS was performed in the Unit 
of Child Neurology by paediatric neurologists and a multiprofessional team. The score of 
the CARS varied from 29 to 41 (mean 34, SD 3) with the IQ (according to the Leiter 
method) ranging from 70 to 109 (mean 88, SD 12); the latter demonstrating that this was a 
group of quite high functioning autistic individuals. 
Baseline information for ATEC was gathered during an interview of the parents by the 
investigator (IM). The study design had been structured primarily to detect changes in the 
clinical condition, not to try to measure the absolute severity of a single feature or 
symptom. Since ATEC is basically a subjective scale, no further analysis of the baseline 
information was considered necessary in the present study.  
In terms of clinical response, there was a statistically significant favorable effect, after 
fluoxetine, on 23 items out of the 77 in ATEC; seven items on speech, language, and 
communication (ATEC 1), eight items concerning socialization (ATEC2), and eight items 
on sensory/ cognitive awareness (ATEC 3) (Table 5.3). There were no statistically 
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significant changes in ATEC items dealing with health and physical conditions or behavior 
(ATEC 4). The positive effects found in the autistic cohort were mainly attributed to a 
subgroup of six subjects who had a particularly high frequency of favorable scores on the 
ATEC 2 scale (i.e., socialization). Therefore, subsequent analyses were carried out by 
dividing the autistic cohort into good (above the ATEC 2 median) and poor (at or below 
the ATEC 2 median) clinical responders (Table 5.1), as there was such a distinctive 
division in the autistic cohort.  
Also in the ATEC 1 (Speech, language, communication) and ATEC 3 (Sensory/cognitive 
awareness) sections, the good response was led by the same subgroup of responders, 4 of 
them in ATEC 1, and 5 of them in ATEC 3, respectively. In ATEC 4, concerning behavior, 
no statistically significant responses were detected; however, a better response in 
stereotyped or repetitive behavior was detected in the good responders compared to the 
poor responders also in this section. 
Post hoc analyses revealed that the six good responders displayed a significant decrease 
in serum BDNF concentrations compared to baseline (p=0.03), in contrast with the seven 
poor responders, who showed an increase in BDNF or no change. In fact, as a group, there 
was a trend towards increased BDNF concentrations among the poor clinical responders 
(p=0.09). SERT binding changes in the midbrain were less pronounced; good clinical 
responders showed minimal or no differences and most responders in the poor response 
group showed an increase. Figure 5.5 illustrates these BDNF and SERT binding profiles in 
terms of scores on the ATEC 2. 
 
Figure 5.5. Change in serum brain derived neurotrophic factor concentrations and in serotonin 
transporter binding in the midbrain, in two groups with different clinical responses to fluoxetine, 
according to the Autism Treatment Evaluation Checklist Section Two, Socialization. Group A 
(good responders, n = 6) had the best clinical response, while group B (poor responders, n = 7) 
experienced a less beneficial clinical effect. Error bars indicate the standard deviations. The 
difference of brain derived neurotrophic factor between the groups was significant. Normalized 
change was calculated as follows: 100 % (treatment - baseline) / 0.5 (treatment + baseline). 
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There was no correlation detected between: changes in BDNF concentrations or SERT 
binding and the baseline cognitive function (i.e. Leiter scale of nonverbal intelligence), or 
severity of autistic behavior (i.e., CARS scores). However, these baseline measurements 
did not correlate with the clinical response during the study. There was also no correlation 
between fluoxetine dosage and any of the above-mentioned variables. 
During the trial, symptoms representing possible drug intolerability or adverse effects 
were detected during the initiation and in the therapy course as the dose were elevated. 
Those symptoms included hyperactivity (n=5), increase in aggressive behavior (n = 5), and 
sleep disturbances (n=4). Reducing the dose or refraining from a further dose increase 
relieved the symptoms. Thus none of the patients needed to discontinue medication 
because of adverse events during the 6-month treatment period. The parents of nine 
autistic subjects requested restart fluoxetine treatment again after the washout period and 
the follow-up investigations had been completed, because in their opinion the positive 
clinical effects outweighed any adverse effects. 
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Table 5.3. Clinical response to fluoxetine in autistic children by the Autism Treatment Evaluation 
Checklist (ATEC). 
 
Parameters Prior to treatment 
* 
After treatment * p-value ** 
Mean (SD) Mean (SD) 
ATEC1: Speech/language/communication    
Can follow some commands 3.3 (0.8) 3.8 (0.7) 0.006 
Knows 10 or more words 3.8 (1.2) 4.4  (0.9) 0.027 
Explains what he/she wants 2.4 (1.1) 3.2 (1.1) 0.007 
Asks meaningful questions 1.6 (1.0) 2.3 (1.6) 0.027 
Speech tends to be meaningful/relevant 2.0 (0.8) 2.9 (1.2) 0.007 
Often uses several successive sentences 1.7 (1.1) 2.1 (1.3) 0.041 
Carries on fairly good conversation 1.3 (0.4) 1.6 (0.7) 0.038 
    
ATEC 2: Socialization    
Seems to be in a shell - cannot be reached 2.5 (1.1) 2.0 (1.0) 0.026 
Ignores other people 3.0 (0.7) 2.5 (0.9) 0.020 
Pays little or no attention when addressed 2.5 (0.9) 2.0 (0.8) 0.007 
No eye contact 2.5 (1.2) 2.1 (0.9) 0.028 
Avoids contact with others 2.8 (0.9) 2.2 (0.7) 0.010 
Does not imitate 2.8 (0.7) 2.4 (0.7) 0.050 
Does not share or show 3.6 (1.0) 3.2 (1.2) 0.037 
Insensitive to other's feelings 3.2 (1.0) 2.8 (1.1) 0.041 
    
ATEC 3: Sensory/cognitive awareness    
Responds to praise 3.8 (0.7) 4.2 (0.5) 0.026 
Aware of environment 3.1 (0.7) 3.4 (0.7) 0.041 
Shows imagination 2.1 (1.1) 2.5 (1.3) 0.004 
Initiates activities 2.7 (0.9) 3.2 (0.9) 0.006 
Dresses self 3.8 (0.6) 4.2 (0.4) 0.011 
Curious, interested 2.9 (0.8) 3.4 (0.8) 0.006 
Venturesome – explores 2.7 (0.9) 3.1 (1.0) 0.010 
"Tuned in" - not spacey 1.9 (0.8) 2.4 (1.0) 0.016 
    
 
* ATEC scale ranged from 1 to 5; in ATEC 1 and ATEC 3 increasing values mean more favorable situation (or treatment 
response), in ATEC 2 decreasing values, respectively.** Wilcoxon signed ranks test 
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6 Discussion  
 
 
6.1 THE STUDY DESIGN 
This study arose from a review of previous research on the importance of the growth 
factors in autism spectrum disorder, including Rett syndrome (Vanhala et al., 1998, 
Riikonen and Vanhala 1999, Vanhala, 2000 and 2001).  Another inspiration was the study 
of Riikonen et al. (2005) on imaging of SERT and DAT by SPECT in children with fetal 
alcohol syndrome, a syndrome with an increased risk of autism (Miles et al., 2003, 
Landgren et al., 2010).  
As described in Chapter 4.2, it was not simple to recruit an autistic cohort for such a 
strenuous and long-lasting study as the present thesis study. To make the sample more 
homogenous, it was decided that the autistic individuals in the study should have neither 
antiepileptic pharmacotherapy nor any other psychotropic medication. All the patients 
had equally good educational and therapeutic facilities, and the present study did not 
attempt to modify those activities. Recruiting autistic individuals into such an intensive 
study is not easy. Diversity in patients´ symptoms and in the severity of their autism could 
not be avoided. It was noted that equalizing all the factors in an autistic population is 
impossible due to individual characteristics and needs. However, the small number of 
patients places certain limitations in the possibilities of evaluating the results, both in 
statistically and clinical respects.  
With respect to fluoxetine therapy, a relatively long duration of the pharmacotherapy 
was regarded as an advantage because autism is a life-long disorder, and the effects of 
fluoxetine treatment may take a long time to become evident. At the end of fluoxetine 
therapy, a 2-month washout period was necessary to avoid that the measurements would 
be affected by the short-term effects in SERT and DAT binding instead of long-term – 
possibly constant – changes in these transporter proteins.  However, the longer follow-up 
time also increases the possibility of confounding factors influencing the lives of the 
subjects being investigated, e.g. changes in day care or school.  
Children and adolescents are vulnerable study subjects. Performing a SPECT scan on 
autistic children with low co-operative skills is challenging, and thus the need for sedation 
was inevitable. In control subjects, this kind of unnecessary sedation would be considered 
unethical. Thus, estimating the effects of sedation in autistic patients could not be avoided. 
However, during the repeated SPECT scan after the fluoxetine treatment, a similar type of 
sedation was used, hence minimizing the effect of sedation in the results.  
 
6.2 HEAD GROWTH 
 
The findings in the present study concerning the head growth patterns of the autistic 
children during the first year of life are consistent with the findings of increased brain (and 
HC) growth occuring during the first year of life in autism (Courchesne et al., 2003, 
Redcay and Courchesne, 2005). In a recently published report of nearly 9000 children 
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followed up to 3 years of age which sought for an association between head growth and 
autism, Barnard-Bark et al. (2011) could not detect any significant correlation, but at 9 
months of age, the individuals who were diagnosed as autistic later had mean HC 1.3 cm 
larger than the typically developing children. This emphasizes the proposal that abnormal 
brain and head growth in autism takes place before the symptoms and signs of autism can 
usually be observed. 
In the present study, a positive correlation between CSF-IGF-1 and HC in the autistic 
subjects was detected. In autism, a disruption of normal neurobiological mechanisms has 
been postulated, but it is not known which mechanisms might be involved in these 
processes. Pathological growth and arrest in brain growth are thought to be restricted to 
the first years of life. The present study was investigating older children (median age 5 y 5 
mo) but even in these children a positive correlation was found between CSF-IGF-1 and 
head growth in autistic children, but not in controls. This suggests that IGF-1 may have an 
essential role in the pathogenesis of the aberrant brain growth in autism. No correlation 
was found between head growth and IGF-2 concentrations.  
Further research should be focused on younger children to elucidate the process of 
brain pathology in autism. The present study suggests that IGF concentrations may play 
an important role in the pathophysiology of autism.  
In general, one is unlikely to be able to obtain CSF samples for analysis of growth 
factors from young children under 2 years of age is, and autism is seldom diagnosed 
before 2 years of age, and invasive procedures in such young children always need special 
permission. In the future, it would be important to evolve non-invasive methods to 
investigate IGFs in young children with a suspicion of autistic development or an 
increased risk of autism, for example, baby siblings of an autistic child. 
 
 
6.3 GROWTH FACTORS 
 
6.3.1 IGF-1 
In the present study, low concentrations of CSF-IGF-1 were detected in the children with 
autism of 5 years of age or younger. This is consistent with the proposal of an early 
perturbation in brain development during prenatal and early postnatal life. Anlar et al. 
(2007) reported lower urinary excretion of IGF-1 in autistic children between 2 to 5 years of 
age as compared with age-matched controls. They reported no correlation between the 
IGF-1 with the severity of the autistic symptoms, i.e. similar to the findings in the present 
thesis study. 
Mills et al. (2007) have reported increased plasma concentrations of IGF-1 and IGF-2 in 
71 autistic children aged 4 to 8 years as compared with age-matched controls. In the 
present study, no correlation was detected between the serum and CSF concentrations of 
IGFs, thus the findings of Mills et al. cannot be directly compared with those in the present 
study. However, interestingly Mills et al. (2007) found a positive correlation between IGF-
1 and HC, but no correlation between IGF-2 and HC, similarly as the results of the present 
study. 
The effects of recombinant IGF-1 in brain growth have been evaluated in children. 
Pediatric patients with Laron syndrome, dwarfism with insensitivity to growth hormone, 
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and very low concentrations of IGF-1, displayed a rapid increase in HC after initiation of 
IGF-1 therapy (Laron, 1999). This reflects the ability of IGF-1 to stimulate brain growth and 
indicates that IGF-1 therapy could be potentially useful in autism. However, further 
studies will be needed to confirm this hypothesis. 
The role of neurotrophic factors, including the IGFs, has been investigated in several 
pediatric disorders involving the central nervous system; including neonatal asphyxia, 
infantile spasms, various white matter diseases, infantile ceroid lipofuscinosis, and autism 
(Riikonen, 2007). Treatment trials for these indications still remain to be conducted in 
pediatric patient populations. 
In animal models, IGF-1 has been effective in treatment of cerebellar ataxia (Fernandez 
et al., 2005) which is interesting in relation to autism since both conditions share the 
characteristics of prominent damage of cerebellar Purkinje cells (Bauman and Kemper, 
2005). The potential use of IGF-1 therapy has also been proposed in certain neuromuscular 
disorders such as muscular dystrophies and amyotrophic lateral sclerosis, yet transferring 
the results of experimental studies to practice in humans has not been done (Jablonka et 
al., 2011). 
 
6.3.2 BDNF 
In the present study, prior to fluoxetine treatment a bimodal distribution of BDNF 
concentrations was detected in the autistic cohort. Although the basis for this finding 
remains unknown, it may represent additional evidence of the heterogeneous etiology and 
pathogenesis of otherwise homogenous autistic behavioral phenotypes. In the present 
study, children with relatively higher baseline BDNF concentrations, who experienced a 
decrease in this biomarker after fluoxetine treatment, exhibited a more beneficial clinical 
outcome. Consistent with this, the behavioral response to antidepressant treatment is 
lacking in depressed individuals with either reduced brain BDNF concentration or 
inhibited signaling of its receptor TrkB (Castren et al., 2007). A certain level of BDNF 
might be required in order to obtain a positive response to SSRIs and this could, at least in 
part, explain the less favorable response in autistic children with low baseline BDNF 
concentrations.  
The decrease in serum BDNF concentrations after fluoxetine treatment, seen in the good 
responder group, may reflect the correction of BDNF hyperactivity. Indeed, excessive 
BDNF can be deleterious for neuronal development, leading to a premature termination of 
cortical plasticity (Huang et al., 1999). Thus, in autism, BDNF may be a factor leading to 
precocious maturation, limiting the brain’s ability to refine its synaptic processes. 
Therefore, a hypothetical target for early intervention in autism would be to decrease 
BDNF signaling via blockade of TrkB receptors or reduction in BDNF synthesis. This 
might possibly extend the period of synaptic plasticity and make it possible to overcome 
the atypical development seen in this disorder (Bethea and Sikich, 2007, Tsai, 2006). 
The findings in the present study are important since excess of BDNF during critical 
periods of development might lead to precocious maturation and thereby limit the brain’s 
ability to readjust to the changing environment and experiences later in life (Hanover at 
al., 1999, Huang et al., 1999).  
Reports on serum BDNF concentrations have been quite inconsistent in the literature. In 
a recent report of serum samples collected at birth, BDNF concentrations were similar in 
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infants who were later diagnosed as autistic or had an intellectual disability, as compared 
with those who enjoyed normal development (Croen et al., 2008). Connolly et al. (2006) 
found elevated serum BDNF concentrations in preschool age children with autism or 
childhood disintegrative disorder, when compared with children with normal 
development or other neurological disorders. They also reported a positive association 
between immunological abnormalities, namely autoantibodies against BDNF and other 
antigens (e.g., myelin basic protein), and BDNF concentrations. These findings are 
consistent with those of  Miyazaki et al. (2004), who found higher BDNF concentrations in 
children and in young adults with autism (and others with intellectual disability) as 
compared with those of healthy adult controls. However, another study demonstrated low 
serum BDNF concentration in adult males with autism (Hashimoto et al., 2006).  
This discrepancy suggests that BDNF concentrations may be variable in autistic 
individuals and that they may also depend on their age. As far as is known, there have 
been neither any longitudinal studies of BDNF concentrations in autistic subjects nor 
evaluations of BDNF changes occuring after treatment of the disorder. For these reasons, 
the findings in the present study represent a contribution to the increasing body of 
literature on the role of BDNF in autism (Connolly et al., 2006, Croen et al., 2008, 
Nishimura et al., 2007). 
In the present study, the genetic background of the autistic individuals was not 
evaluated except for ruling out major chromosomal disorders and fragile X syndrome. 
However, the importance of growth factors has been emphasized in autism models in 
some genetic disorders. In most cases of Rett syndrome, the mutated protein MeCP2 
seems to regulate BDNF transcription, and cortical BDNF concentrations are reduced in 
mouse models (Kaufmann et al., 2005). Furthermore, BDNF polymorphisms appear to 
modify the propensity to seizures that are a key phenotypical feature in Rett syndrome 
(Zeev et al., 2009). However, in the study of Vanhala et al. (2001) no difference in serum 
BDNF concentrations was detected between autistic children and age-matched controls. 
Experimental studies have revealed that BDNF can regulate the expression of the fragile 
X mental retardation protein in neuronal cell cultures, and an overexpression of BDNF 
receptors TrkB has also been detected in these cells (Castren et al., 2002). In patients with 
fragile X syndrome, an association between vulnerability to epilepsy and BDNF gene 
polymorphisms has been reported recently (Louhivuori et al., 2009). Tsai (2005) has 
postulated that early BDNF hyperactivity may represent a critical factor in the origin of 
autism as well as an explanation for the increased incidence of epilepsy in autism. In the 
present study, a bimodal distribution of BDNF concentrations was detected, but none of 
the autistic individuals had epilepsy, thus, one cannot draw any further conclusions about 
the role of BDNF and vulnerability to epilepsy. 
The effects of BDNF are mediated mainly through its TrkB receptor (Binder and 
Scharfman, 2004). Tsai (2005) has postulated that overexpression of BDNF-TrkB would be 
implicated in the pathogenesis of epilepsy, mania and autism. Thus, TrkB might be a 
potential target for pharmacological compounds in the treatment of these disorders. 
Peptide molecules targeting TrkB as partial agonists with respect to BDNF have been 
developed and tested in cell cultures (O’Leary and Hughes, 2003), but it will be a long 
time before they reach clinical use.  
In the present study, it would have been interesting to determine the BDNF 
concentration in CSF; in fact this was an initial aim. However, the detection level of the 
analytical method was not sufficiently sensitive for this measurement. Not surprisingly, 
there are no studies reporting successful measurement of CSF-BDNF in autistic children. 
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In patients with Rett syndrome, Vanhala et al. (1998) reported that CSF-BDNF 
concentrations were below the detection threshold. In another context, a recent report of 
adult patients with posttraumatic stress disorder claimed that the concentration of CSF-
BDNF and CSF-IGF-1 did not differ between the patients and the controls (Bonne et al., 
2011). Moreover, the concentrations BDNF and IGF-1 in CSF were not related to the 
clinical response to paroxetine, a drug in the SSRI family, given to the patients with post-
traumatic stress disorder (Bonne et al., 2011)..  
The bimodal distribution of BDNF concentrations detected in the present study has not 
been reported in earlier studies in autism and certainly needs to be confirmed in future 
studies. However, it is noteworthy that a wide range of inter-individual variation of BDNF 
concentrations has been detected in autism. Miyazaki et al. (2004) found a 7-fold variation 
in serum BDNF concentrations, but the inter-individual variation of the BDNF 
concentrations in healthy control children was almost equally wide.  This may reflect 
either the general heterogeneity in BDNF concentrations or the variance in backgrounds of 
autism, but it does emphasize the difficulty in the interpretation of an individual 
measurement at one certain moment. Thus, BDNF concentrations in autism must be 
interpreted with caution until confirmatory studies with more subjects have been 
performed. 
At the time when the present study was carried out, no reports on the possible effect of 
pubertal status in BDNF concentrations had been reported. Recently, Iughetti et al. (2011), 
detected lower plasma BDNF concentrations in pubertal boys as compared with pre-
pubertal boys, or  in girls regardless of their pubertal status. In this thesis study, 10 autistic 
children (9 boys and 1 girl) aged 11 years or below were clearly in pre-puberty, 4 boys 
aged 12-13 years were in mid-puberty, and 1 boy aged 16 years in late puberty. No 
statistical correlations with serum BDNF concentration and age or pubertal status could be 
detected in post-study calculations. Neither pubertal status nor body mass index was 
recorded in the controls.  
Furthermore, lower serum concentrations of BDNF have been reported in typically 
developing children and adolescents who are overweight as compared with their normal-
weighted peer (El-Gharbawy et al., 2006), but in the present study no correlation was 
detected between serum BDNF concentration and the body mass index. 
 
6.4 MONOAMINE TRANSPORTERS 
 
6.4.1 SERT 
In children and adolescents with autism, there had been conducted no research into 
monoamine transporters, SERT and DAT, binding capacity with SPECT at time when the 
present study was designed and launched at the end of 2003. Later Nakamura et al. (2010) 
have reported SERT binding capacity in autism, but they investigated autistic adults with 
PET. 
In the present study, prior to fluoxetine treatment, a lower SERT binding capacity was 
detected in MFC (equivalent to anterior cingulate cortex), in midbrain, and in temporal 
lobes of individuals with autism as compared with the non-autistic control children. The 
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difference became more evident with increasing age as SERT binding in autistic subjects 
decreased with age whereas in control subjects, SERT increased. Chugani et al. (1997) have 
evaluated the serotonergic system with PET in autistic children, and the results of that 
study can be contrasted with the findings of the present study. Chugani et al. (1997) 
indicated that children with autism lack an early peak in serotonin synthesis during the 
first 5 years of life. In the present study, the lower SERT binding capacity in brain in the 
autistic individuals may reflect a reduced serotonin synthesis capability during the 
preceding years. The observation of the ongoing decrease in SERT with age in the present 
study indicates that the delayed increase in serotonin synthesis towards adolescence 
found by Chugani et al. (1997) may not be sufficient to compensate for the early emerging 
deficit.  
Another interesting relationship with the profile of serotonin synthesis capacity has 
been pointed out by Bethea and Sikich (2005); in post-mortem specimens from children, 
the profile of synaptic density during infancy and childhood demonstrated by 
Huttenlocher (1979) resembles that of the development of serotonin synthesis. There have 
been no studies into synapse density in brain tissue of young autistic patients. 
The relationship between the serotonergic system and autism has been investigated in 
experimental studies. Boylan et al. (2007) reported that depletion of serotonergic neurons 
in the bilateral medial forebrain bundle in mice evoked a reduction in SERT density in 
cortex and hippocampus, and to social and behavioural impairments akin to those seen in 
autism. The observations by Boylan et al. (2007) support the interpretation that early 
serotonergic aberration in children with autism might lead to decreased serotonergic 
synapse density, and further to the evolution of the differences in SERT binding capacity. 
In the present study, SERT binding capacity was lower in all evaluated regions, before the 
estimated correction of effects of sedation was performed.  
Findings consistent with the present study have been recently presented by Nakamura 
et al. (2010) in a PET study with adult men with high functioning autism. They found low 
SERT binding density in cingulate cortex (equivalent to MFC in the present study) and 
thalamus. Moreover, this reduced SERT binding displayed a positive correlation with 
impairments in social cognition and repetitive and/or obsessive behavior (Nakamura et al., 
2010).  
Incorporating a genetic study with polymorphism of SERT gene into the present study 
would have been interesting, because SERT gene polymorphism has been investigated in 
autism (Devlin et al., 2005). However, the resources in the present study were not 
available to undertake this kind of examination.  
In the present study, after the 6-months of pharmacotherapy with fluoxetine and the 2-
months washout period, a trend was detected towards an increase in SERT binding 
capacity both in MFC and in midbrain. The initial hypothesis in the present study was that 
fluoxetine might increase the serotonergic activity, and in that way also SERT binding 
capacity, through the effect of growth factors IGF-1 and/or BDNF. However, no correlation 
was detected between the changes in SERT binding and those of in IGF-1 and BDNF 
concentrations. Despite the lack of any significant relationship between fluoxetine 
treatment and the increase in SERT binding, it can be speculated that fluoxetine treatment 
did cause a trend towards changes in serotonergic metabolism in MFC and in midbrain. 
Serotonin and BDNF are associated with the pathogenesis of some neurological disorders, 
including Alzheimer’s disease (Mattson et al., 2004). Thus, further studies evaluating 
BDNF and serotonin interactions should be conducted also in autistic populations.  
There are several possible mechanisms that can be involved in SERT binding capacity; 
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the concentration of serotonin in the synapse, the density or affinity of transporters, or the 
actual number and density of synapses themselves. Based on the data about serotonin 
synthesis capacity in children and adolescents with autism, the most plausible 
interpretation of the results of the present study is that the decline in SERT binding 
capacity was due to a reduced number of serotonergic synapses and number of serotonin 
transporters.  
 
6.4.2 DAT 
Before the fluoxetine treatment, DAT binding in striatum of autistic children was highest 
in the youngest individuals, and then decreased towards adolescence, but in the age-
matched controls DAT binding increased with age.  
Xiao-Mian et al. (2005) reported increased striatal DAT binding in 10 autistic boys aged 
between 3 and 10 years as compared with normally developing controls. The findings in 
the present study in autistic individuals below 10 years of age are consistent with those in 
the study of Xiao-Mian et al. (2005). In a PET study, Nakamura et al. (2010) reported 
higher DAT binding in orbitofrontal cortex in adult autistic men. 
The results of the present study, along with those of Xiao-Mian et al. (2005) and 
Nakamura et al. (2010), can be interpreted as being in agreement with with the theory of a 
hyperdopaminergic state in the etiology of autism as proposed by Previc (2007). In that 
theory, Previc (2007) introduces the idea that maternal and environmental risk factors 
during pregnancy, and soon after birth, create a hyperdopaminergic state that is 
devastating for the development of brain. Previc has proposed this hyperdopaminergic 
theory as an explanation for the rapid increases in the occurrence of autism. In the present 
study, an increase in CSF IGF-1 could have a neuroprotective effect against the 
neurotoxicity induced by the hyperdopaminergic state. 
The present study is the first to have undertaken striatal DAT measurements in 
response to fluoxetine treatment in autistic individuals. After fluoxetine treatment, 
interesting changes were detected in striatal DAT binding. The six autistic patients with 
the favorable clinical response had a decrease in DAT binding capacity. In contrast, those 7 
children out of 13 who gained less benefit from pharmacotherapy displayed no change or 
a slight increase in DAT binding capacity. As there are no comparable pharmacotherapy 
studies in autism, comparisons have to be done with studies performed in other 
neuropsychiatric disorders. Kim et al. (2006) reported a decrease in DAT density in the 
basal ganglia in 10 adult patients with obsessive compulsive disorder after a 16-week 
treatment with SSRIs, including fluoxetine and all patients were reported to have enjoyed 
a clinically good response. The results in the present study are consistent with those 
findings. As in the patients with obsessive compulsive disorder, a decrease in DAT 
binding capacity was detected in the autistic children with a good clinical response to 
fluoxetine. However, DAT binding capacity prior to treatment was not a predictive value 
in this autistic population.  
SSRI therapy also affects the dopaminergic system: Hood et al. (2010) reported a study 
of adults with social anxiety disorder, introducing an experiment with a dopamine 
activation condition (with pramipexole) or a dopamine blockade condition (with 
sulpiride). Those patients that had not received any preceding SSRI pharmacotherapy 
displayed increased anxiety in both dopamine activation and dopamine blockade 
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condition, but the patients with SSRI therapy had significantly less anxiety during the 
same tests.  Hood et al. (2010) concluded that SSRIs probably desensitize dopamine 
receptors in the limbic system, and therefore they alleviate the patients’ anxiety response 
to dopaminergic stress. On the other hand, Segawa (2006) has presented a theory of 
supersensitization of dopamine receptors in autism, and they reported improvement in 
undesired awakenings during night sleep, decrease in aggressiveness and panic states, 
and less hyperkinesia in autistic children after administration of small doses (0.5mg/kg/d) 
of L-dopa. Segawa interprets the beneficial effects of L-dopa to be mediated probably 
through desensitization of dopamine receptors. 
In conclusion, there is growing evidence for an interplay between SERT and DAT 
functioning. It is important to remember that SSRIs like fluoxetine act on both serotonin 
and dopamine systems.  
 
6.5 CLINICAL EFFECTS OF FLUOXETINE 
 
The main purpose of providing fluoxetine therapy was to investigate the connections 
between the growth factors and monoamine transporters, as reported in the previous 
chapters.  
In the present study, significant favorable effects were detected on 23 out of the 77 items 
in ATEC although it took several weeks for the positive response to emerge. Mostly, the 
favorable responses were seen at 12 weeks after the initiation of fluoxetine treatment, and 
the response was most evident at the end of the 6-month treatment period.  
The variety in favorable response was wide ranging; positive effects on sociability 
(ATEC 2) and sensory/cognitive awareness (ATEC 3) were more prominent than those in 
speech, language and communication (ATEC 1). The results in the present study were 
somewhat different from those reported by DeLong et al. (1998 and 2002) in autistic 
children, as they reported positive effects of fluoxetine mainly on language and 
communication. In addition, DeLong et al. (1998) described marked responses already 
during the first weeks of treatment, and in some individuals, the improvement was so 
great that they reported that those patients no met the criteria of autism. In the present 
study, the onset and degree of beneficial responses was less significant and all subjects still 
met the criteria for autism after fluoxetine therapy.  
The time span of several weeks between the start of fluoxetine treatment before the 
emergence of the clinical response is consistent with the findings in studies with other 
patient groups, for example subjects with depression. It has been postulated that the 
response may take time because of changes in neuronal networks need time to become 
established and consolidated. In these mechanisms, growth factors, especially BDNF, are 
believed to play a critical role (Castren, 2004, Castren and Rantamäki, 2010). 
The positive effects found in the autistic cohort were mainly attributable to a subgroup 
of six subjects, the good responders, who had a particularly high frequency of favorable 
scores on the ATEC 2 scale (socialization). In the seven subjects with less beneficial clinical 
response, symptoms concerned with obsessive-compulsive-like behavior or stereotypic 
behavior did not differ during the baseline or at the end of treatment. Thus, it was not 
possible to repeat the recent observations by Hollander et al. (2005) as they reported a 
decrease of repetitive behaviors in children with autism after an 8-week fluoxetine 
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therapy. In another recent placebo-controlled study with citalopram (an SSRI drug) 
therapy for 12 weeks, there was no significant response detected in repetitive behavior 
symptoms in children with ASD (King et al, 2009).  
The true clinical significance of the therapy responses measured by ATEC and the 
actual relief experienced during fluoxetine therapy are difficult to estimate and quantify: 
change of one point in ATEC cannot be compared between subjects precisely. However, 
the general improvement during fluoxetine treatment is emphasized by the fact that the 
parents of nine autistic subjects requested that fluoxetine treatment should be reinstalled 
again after this study had been completed. They stated that the positive clinical effects and 
experiences during the fluoxetine therapy clearly outweighed any adverse effects or the 
trouble of remembering the daily dose of medicine. The favorable clinical response for 
fluoxetine treatment was evident, but the lack of placebo group leads to uncertainty about 
whether one can generalize those results. 
 
 
6.6 FUTURE PERSPECTIVES 
 
Investigating correlations between the genetic factors and the inter-individual variation in 
the anatomical and physiologic findings in brain might provide a way of making rapid 
progress in clarifying the etiology of autism. It can be seen already now that the realization 
that those genetic disorders in which there is increased incidence of autism have revealed 
the involvement of some putative novel mechanisms in the pathogenesis of autism. A 
minority of autistic subjects can be identified who present a syndromic background like 
fragile X syndrome, tuberous sclerosis or major anatomical defects of central nervous 
system, but more detailed genetic susceptibility or more sophisticated neuroanatomical, 
and metabolic connections have been described (Miles, 2011, Ecker et al., 2010, Benvenuto 
et al, 2009, Schiff et al., 2011). However, the great majority of autistic individuals do not 
have any of those single-gene syndromes for which tests are available today. Thus, 
mapping more genes in non-syndromic autistic patients could have great importance. 
Genetic testing is also much easier to performe than using different imaging methods or 
neurophysiological tests.  
However, genetic factors alone are most unlikely to provide all the solutions. The 
development of new non-invasive methods for the examination of the nervous system, 
such as functional MRI, transcranial magnetic stimulation and diffusion tensor imaging 
might represent new possibilities since they could lower the threshold lower to undertake 
examinations for individuals with a reduced ability to co-operate, such as children with 
autism. New generations in SPECT and PET scanners with higher capacity and thereby 
more rapid imaging with less radiation exposure would also be helpful. The non-invasive 
and patient-friendly methods would make it possible to expand the studies to include the 
youngest children in whom there are initial suspicions of autism, or even simply an 
increased risk of autism, such as siblings of autistic children. Thus, clarifying the early 
phases of autistic development could be possible. 
Autism is a heterogeneous entity and the additive nature of different factors often 
makes the results difficult to interpret. Therefore, more details about the clinical 
characteristics of autistic individuals could help to achieve more relevant results, even in 
respect of the genetic or neurophysiologic studies: e.g. it is probable that the 
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heterogeneous phenotypes of autism have also heterogeneous genotypes. Thus, gathering 
clinical information by interviewing parents and undertaking observations during 
diagnostic studies or follow-up visits should record the individual characteristics 
collecting as many specific details as possible. This would make different studies more 
comparable and contribute to developing more detailed study designs in the future.  
It is not easy to obtain a carefully selected study sample of autistic patients. In Finland 
there is no distinct research center specializing in autistic individuals. Childhood autism is 
a rather rare disorder, and the population of Finland is rather small, 5.4 million 
inhabitants. According to the latest predictions, the yearly incidence will be about 60 new 
cases of childhood autism, and 180-240 with other autism spectrum diagnoses in Finland. 
As the population is scattered over a relatively large area and transportation from the 
home to a research center could be troublesome for autistic patients,   good collaboration 
between physicians and hospitals would benefit the research in this field of science.  
In the near future, new revisions of both DSM and ICD will be published. However, a 
new diagnostic methodology can make it difficult to compare the results of studies 
performed during different decades, as patients would have been selected with different 
criteria. In Finland, Mattila et al. (2011) have recently published an epidemiological study 
comparing DSM-IV Text Revision (American Psychiatric Association, 2000) and DSM-5 
draft criteria (www.dsm5.org) for autism spectrum disorders, screening an age cohort of 
more than 5,000 children aged 8-years in Northern Finland. By applying the DSM-5 draft 
criteria in the cohort which had been earlier diagnosed with DSM-IV Text Revision 
criteria, the researchers reported a remarkable decrease in number of subjects meeting the 
criteria, especially in those subjects with high functioning autism or Asperger syndrome. 
This emphasizes the challenge in defining the diagnostic criteria of ASD. 
Another interesting aspect in autism research is the difficulty in making a differential 
diagnosis between ASD and the presentation of autistic traits in general population. This 
seems to be due to the fact that in individuals with Asperger syndrome or pervasive 
developmental disorder not otherwise specified, the degree of symptom severity or 
behavioral impairment shows an interaction with environmental factors (Baron-Cohen et 
al., 2009). Individuals with autistic traits, like family members and relatives of individuals 
with ASD, might represent an interesting population for autism research, and they would 
be much more cooperative than the autistic patients themselves.  
In the future it would be interesting to combine pharmacologic and conventional 
therapeutic methods with neurobiological research targets. However, this would require a 
precise selection of patients and detailed psychological studies prior to the therapeutic 
intervention. A multidisciplinary study group would be necessary for conducting these 
kinds of projects. However, small clinics with limited resources can succeed with well 
focused studies with relatively small patient populations, as the present study 
demonstrated. 
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7 Conclusions 
 
The first aim of the present study was to measure growth factors IGF-1, IGF-2, and to 
correlate them with head growth, secondly to evaluate monoaminergic neurotransmission, 
through evaluation of SERT and DAT as determined by SPECT, and thirdly to evaluate 
BDNF in serum and in CSF, in autistic children and adolescents, and thereafter to 
undertake 6-months of pharmacotherapy with fluoxetine, and to evaluate the effects of 
fluoxetine on levels of IGF-1, BDNF, SERT, DAT, as well as in the clinical response.  
 
The main conclusions that can be drawn from this study are: 
 
1. Cerebrospinal fluid IGF-1 concentration was lower in the younger autistic 
children under 5 years of age compared with controls. The lower IGF-1 
concentration might account for the aberrations in neurobiological mechanisms 
and be an etiopathogenetic link to loss of cerebellar Purkinje cells.  
There was a positive correlation between the HC and CSF-IGF-1 concentration 
in autistic children but not in the children with normal development. This 
might reflect a different response to IGF-1 in autistic individuals as 
comparedwith normally developing children. 
 
2.  Serotonin transporter binding capacity was lower in the SPECT imaging in 
MFC and in midbrain of the autistic children compared to age-matched non-
autistic comparison children. This finding confirms the suspicions that there is 
disruption to the serotonergic dysfunction in autism.  
Prior to fluoxetine treatment, striatal DAT binding displayed a different 
correlation  with the age of the individuals in the autistic group and in the 
comparison group. The DAT binding was highest in the youngest autistic 
patients and then decreased with the age but in the comparison children, DAT 
binding increased  with age. This is pointing to the existence of an early 
hyperdopaminergic state in autism which might provide inappropriate 
conditions for neuronal development and survival. 
 
3.  Prior to treatment, a bimodal distribution was detected in the serum BDNF 
concentration in the autistic subjects, and the inter-individual variation in 
BDNF concentrations was higher in the autistic subjects, as compared with the 
 controls, highlighting the heterogeneity in autistic individuals. 
 
4. After 6-months of fluoxetine treatment: 
 
a. A positive clinical response in several aspects of communicational, social 
and cognitive functions was detected. This beneficial response was most 
evident in a subgroup of six autistic patients, the good clinical responders. 
b. In the good clinical responders, the beneficial effects of fluoxetine were 
associated with a decrease in serum BDNF concentration. 
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c. A slight increase in SERT binding capacity was detected both in MFC and in 
midbrain, but this change was not significant. The changes in SERT binding 
capacity did not correlate with the clinical response. 
d. In the good clinical responders, DAT binding decreased, but remained 
unchanged or even increased in those with poor clinical response. 
e. An increase in the CSF IGF-1 concentration was detected but the change 
exhibited no correlation with the clinical response. The increase in CSF-IGF-
1 could have a neuroprotective effect against the neurotoxicity induced by 
the early hyperdopaminergic state. 
 
However, the extensive inter-individual variation in the concentrations of growth 
factors and in the binding capacities of SERT and DAT was too large to have any direct 
implications on the everyday practice with autistic individuals.  
A favorable clinical response for fluoxetine treatment was detected, but the lack of 
placebo group makes it difficult to generalize the results. Fluoxetine treatment was 
associated with only a low incidence of adverse events, evidence that fluoxetine treatment 
was well tolerated. Fluoxetine could be considered a safe choice of pharmacotherapy in 
selected patients; it may improve sociability, communicative skills, and sensory awareness 
in children and adolescents with autism. However, no medication is believed to be able to 
improve the symptoms and behavior of the autistic individuals alone, but in combination 
with behavioral, occupational, psychological, and speech therapies, it could represent a 
valuable adjuvant in a condition with few treatment options available. 
The results of this study suggest that fluoxetine may modulate the monoaminergic 
system and neuronal growth factors, which are disturbed in autistic individuals. By acting 
on these factors fluoxetine may promote recovery and restore connections of cerebellar 
Purkinje cells. This finding indicates that fluoxetine may have an influence on the 
development of communication and social interaction skills, both of which are seriously 
disturbed in autism.  
Future research focusing on the early process of brain pathology and relevant genes, it 
will likely be critical in elucidating the etiology of autism and in developing rational 
treatments. Treatment should be given as early as possible to support the normal synaptic 
development and the survival of neurons and their connections, including the cerebellar 
Purkinje cells. 
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APPENDICES 
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ORIGINAL PUBLICATIONS (I-IV) 
 
 
 
 
 
 
 
 

Kuopion Yliopistollinen Sairaala 
Lastenklinikka / Lastenneurologian yksikkö  
 
LAPSUUSIÄN AUTISMIN FLUOKSETIINIHOIDON SEURANTALOMAKE 
 
Merkitään väitteen tai havainnon sopivuus lapseen asteikolla 1-5 siten, että  
1= ei sovi lainkaan, 5= sopii täysin (myös desimaalilukujen, esim. 3,5 käyttäminen on 
mahdollista, jolloin etenkin seurannan aikana mahdollisesti tapahtuvan muutoksen 
merkitseminen helpottuu) 
 
Potilas _____________________________ Lääkitys_______________________ 
 
 
Alkamispäivämäärä_________________ 
 
 
Lääkitys 
päivämäärä          
annos          
 
 
 
I. Puhe/ Kieli/ Vuorovaikutus    
1. tuntee oman nimensä          
2. reagoi "ei" tai "seis" sanoihin          
3. pystyy noudattamaan joitakin 
kehotuksia 
         
4. osaa käyttää yhtä sanaa 
kerrallaan 
         
5. osaa käyttää kahta sanaa 
kerrallaan 
         
6. osaa käyttää kolmea sanaa 
kerrallaan 
         
7. tuntee enemmän kuin 10 
sanaa 
         
8. osaa käyttää yli 4 sanan 
lauseita 
         
9. osaa kertoa sen mitä haluaa          
10. osaa tehdä kysymyksiä, 
jotka ovat mielekkäitä 
         
11. puheen sisältö asiaan 
liittyvää ja merkityksellistä 
         
12. käyttää usein puhuessa 
useita lauseita peräkkäin 
         
13. pystyy juttelemaan/ keskus-
telemaan ikätasonsa mukaisesti 
         
14. pystyy ikätasonsa 
mukaiseen normaaliin 
vuorovaikutukseen 
         
 
 
 
 
II. Sosiaaliset taidot 
1. on kuin kuoren sisällä 
tavoittamattomissa 
         
2. jättää toiset ihmiset 
huomioimatta 
         
3. ei kiinnitä lainkaan tai vain 
vähän huomiota sitä häneltä 
aktiivisesti pyydettäessä 
         
4. ei suostu yhteistyöhön tai 
vastustaa voimakkaasti 
         
5. ei tule katsekontaktiin          
6. jää mieluummin yksin kuin on 
toisten kanssa 
         
7. ei osoita kiintymystä          
8. ei tervehdi / ilahdu 
vanhempien tullessa paikalle 
         
9. välttää ottamasta kontaktia 
toisiin ihmisiin 
         
10. ei matki / jäljittele toisten 
toimintoja tai leikkejä 
         
11. ei pidä sylissä olemisesta tai 
hellimisestä 
         
12. ei esittele toisille tai jaa 
toisten kanssa itselleen tärkeitä 
asioita (esim. lelut, leikit, 
harrastukset) 
         
13. ei vilkuta hyvästiksi "hei hei"          
14. vaikeasti suostuteltavissa, 
"vastarannan kiiski"  
         
15. saa kiukkukohtauksia tai 
"raivareita" 
         
16. ei kavereita kerhossa tai 
koulussa 
         
17. hymyilee vain harvoin          
18. ei reagoi toisten tunteisiin          
19. ei ole kiinnostunut siitä, että 
toiset hänestä pitäisivät 
         
20. suhtautuu vanhempien 
poistumiseen erotilanteissa 
välinpitämättömästi 
         
 
 
 
 
 
III. Sensorinen/ Kognitiivinen tietoisuus 
1. reagoi omaan nimeensä          
2. reagoi kehumiseen          
3. katsoo kohti ihmisiä ja eläimiä          
4. katselee kuvia ja televisiota          
5. piirtää ja värittää          
6. leikkii leluilla tavanomaisella 
tavalla 
         
7. kasvonilmeet kuvastavat 
sisäisiä tunnetiloja  
         
8. ymmärtää TV-ohjelmista 
juonen 
         
9. ymmärtää selityksiä          
10. tiedostaa ympäristönsä          
11. tiedostaa vaaran          
12. osoittaa mielikuvitusta          
13. aloittaa toimintoja/ leikkejä 
omatoimisesti 
         
14. osaa itse pukea          
15. on utelias, kiinnostunut 
asioista 
         
16. tutkii itse, ottaa selvää          
17. on muiden kanssa "samalla 
aaltopituudella", ei "ulkona" 
         
18. katsoo sinne minne muutkin 
katsovat 
         
 
 
 
IV. Yleinen terveydentila / Käyttäytyminen/Lääkityksen mahdolliset sivuvaikutukset 
1. yökastelua          
2. päiväkastelua          
3.muita virtsaamisvaivoja          
4. tuhrimista (kakkaa housuun)          
5.ripulia          
6.ummetusta          
7.vatsakipuja          
8.pahoinvointia          
9.unettomuutta          
10.levoton uni/ painajaisia          
11.syö liikaa          
12.syö liian vähän          
13.liiallista painonlaskua          
14. liiallista painonnousua          
15. ruokavalio erittäin rajoittunut          
16. motorista levottomuutta          
17 liian hidasliikkeinen          
18. lyö tai vahingoittaa itseään          
19. lyö tai vahingoittaa muita          
20. hajottaa tavaroita / leluja          
21. yliherkkä äänille          
22.rauhaton, hermostunut tai 
pelokas 
         
23.lihaskramppeja tai 
nykimisoiretta 
         
24.vapinaa          
25.päänsärkyä          
26.hikoilua          
27.sydämentykytystä          
28.ihottumaa          
29 onneton tai itkuherkkä          
30. kohtausoireita (jos niin 
millaisia?) 
         
31. pakonomaista 
puhumista/ääntelyä 
         
32. jäykkiä rutiinitoimintoja          
33. huutaa tai kirkuu          
34. vaatii samanlaisuutta, 
vastarinta kaikille muutoksille 
         
35. usein kiihtynyt tai ärtynyt          
36. ei reagoi kivulle lainkaan tai 
poikkeavan vähän 
         
37. äärimmäisen kiintynyt tai 
sitoutunut joihinkin esineisiin tai 
asioihin 
         
38. toistaa samoja liikkeitä tai 
eleitä, maneereja 
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Ismo Makkonen
Childhood Autism 
Aspects of Growth Factors and
Monoaminergic Transporters
in Etiopathogenesis
Ismo Makkonen
Childhood Autism
Aspects of Growth Factors and Monoaminergic 
Transporters in Etiopathogenesis
In autism, abnormalities in growth 
and development of brain structures 
have been detected as well as altera-
tions in the serotonergic system. This 
study investigated the relationships 
between growth factors, monoam-
inergic transporters and autism in 
children. The efficacy of fluoxetine, a 
selective serotonin reuptake inhibi-
tor, on these parameters was evalu-
ated. Positive effects on the clinical 
symptoms of autism were detected, 
indicating that fluoxetine might 
represent a useful adjunct to other 
therapies in children with autism.
